1
|
Ghazy RM, Gebreal A, El Demerdash BE, Elnagar F, Abonazel MR, Saidouni A, Alshaikh AA, Hussein M, Hussein MF. Development and validation of a French questionnaire that assesses knowledge, attitude, and practices toward Marburg diseases in sub-Saharan African countries. Public Health 2024; 230:128-137. [PMID: 38537496 DOI: 10.1016/j.puhe.2024.01.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2023] [Revised: 01/13/2024] [Accepted: 01/29/2024] [Indexed: 04/16/2024]
Abstract
OBJECTIVES Marburg virus, previously referred to as Marburg hemorrhagic fever, is a highly severe and frequently fatal illness that affects humans. This study aimed to develop and validate a French questionnaire to assess knowledge, attitude, and practice toward Marburg virus disease (FKAP-MVD). STUDY DESIGN An anonymous online survey was used, which was distributed through various platforms and emails. Data were collected from Burkina Faso, Guinea, the Democratic Republic of Congo, and Senegal. METHODS To conduct the study, an anonymous online survey was used, which was distributed through various platforms such as Facebook, Twitter, WhatsApp, and emails. The survey was uploaded onto a Google form to facilitate data collection. Data were collected from Burkina Faso, Guinea, the Democratic Republic of Congo, and Senegal. RESULTS Of the total sample of 510 participants, 60.0% were male, their mean age was 28.41 ± 6.32 years, 38.0% were married, 86.6% resided in urban areas and 64.1% had a university education. The questionnaire had good internal consistency; Cronbach's alpha was 0.87. The correlation between knowledge and attitude was 0.002, the correlation between knowledge and practice was 0.204, and the correlation between practice and attitude was relatively weak and negative at -0.060. This indicates the divergent validity of the questionnaire. The KMO value of 0.91 indicates a high level of adequacy, suggesting that the data are suitable for factor analysis. The Bartlett test of Sphericity yielded an approximate χ2 value of 4016.890 with 300 degrees of freedom and a P-value of 0.0001. The confirmatory factor analysis revealed 25 questions in three domains. The normed chi-square value is 1.224. The goodness of Fit Index (GFI) is 0.902, the Comparative Fit Index (CFI) is 0.982, the Root Mean Square Error of Approximation (RMSEA) is 0.033, and the Root Mean Square Residual (RMR) is 0.062. These values indicate a good fit of the model to the data. CONCLUSIONS In general, the developed questionnaire has significant potential to inform public health initiatives and interventions related to MVD.
Collapse
Affiliation(s)
- R M Ghazy
- Family & Community Medicine Department, College of Medicine, King Khalid University, Abha, Saudi Arabia; Tropical Health Department, High Institute of Public Health, Alexandria University, Alexandria, Egypt.
| | - A Gebreal
- Faculty of Medicine, Alexandria University, Egypt.
| | - B E El Demerdash
- Department of Operations Research and Management, Faculty of Graduate Studies for Statistical Research, Cairo University, Egypt.
| | - F Elnagar
- Health Administration and Behavioral Sciences, High Institute of Public Health, Alexandria University, Egypt.
| | - M R Abonazel
- Department of Applied Statistics and Econometrics, Faculty of Graduate Studies for Statistical Research, Cairo University, Egypt.
| | | | - A A Alshaikh
- Family & Community Medicine Department, College of Medicine, King Khalid University, Abha, Saudi Arabia.
| | - M Hussein
- Clinical Research Administration, Alexandria Health Affair Directorate, Egypt; Ministry of Health and Population, Egypt.
| | - M F Hussein
- Occupational Health and Industrial Medicine Department, High Institute of Public Health, Alexandria University, Alexandria, Egypt.
| |
Collapse
|
2
|
Shirodkar K, Hussein M, Balogh P, Azzopardi C, Botchu R. Painless knee mass in a young adult: answer. Skeletal Radiol 2024:10.1007/s00256-024-04682-8. [PMID: 38642303 DOI: 10.1007/s00256-024-04682-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/08/2024] [Revised: 04/02/2024] [Accepted: 04/12/2024] [Indexed: 04/22/2024]
Affiliation(s)
- K Shirodkar
- Department of Musculoskeletal Radiology, Royal Orthopedic Hospital, Bristol Road South, Northfield, Birmingham, UK
| | - M Hussein
- Department of Musculoskeletal Radiology, Royal Orthopedic Hospital, Bristol Road South, Northfield, Birmingham, UK
| | - P Balogh
- Department of Musculoskeletal Pathology, University Hospitals of Birmingham, Birmingham, UK
| | - Christine Azzopardi
- Department of Musculoskeletal Radiology, Royal Orthopedic Hospital, Bristol Road South, Northfield, Birmingham, UK
| | - R Botchu
- Department of Musculoskeletal Radiology, Royal Orthopedic Hospital, Bristol Road South, Northfield, Birmingham, UK.
| |
Collapse
|
3
|
Issa PP, McCarthy C, Hussein M, Albuck AL, Emad E, Shama M, Moroz K, Toraih E, Kandil E. Assessing Adequacy: A Meta-Analysis of Rapid Onsite Evaluation of Thyroid Nodules. J Surg Res 2024; 296:523-531. [PMID: 38330678 DOI: 10.1016/j.jss.2024.01.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2023] [Revised: 12/27/2023] [Accepted: 01/07/2024] [Indexed: 02/10/2024]
Abstract
INTRODUCTION Fine-needle aspiration (FNA) is the standard form of preoperative evaluation of thyroid nodule cytological status. A significant number FNAs are classified as inadequate for interpretation, requiring a repeat FNA which is potentially avoidable, costly, and delays treatment. To address these concerns and maximize first-time FNA adequacy, rapid onsite evaluation (ROSE) of FNA specimens was introduced. Our study aims to determine the impact of ROSE on FNA adequacy. METHODS PubMed, Embase, and Web of Science were searched for primary articles assessing the adequacy of ROSE in thyroid nodules. RESULTS A total of 17 studies were included for a total of 24,649 thyroid nodes. Thirteen thousand two hundred fifteen (53.6%) thyroid nodules were assessed utilizing ROSE and 11,434 (46.4%) were not. Pooled adequacy increased significantly from 76% without ROSE to 92% with rose (P = 0.001). Use of ROSE increased the odds of adequate FNA by 22% (risk ratio (RR) = 1.22, 95% confidence interval (CI) = 1.12-1.32). At institutions with less than 85% effective diagnostic adequacy without ROSE, the risk for diagnostic adequacy increased by 28% with ROSE implementation (RR = 1.28, 95% CI = 1.20-1.37). In contrast, in studies reported from institutions with an effective diagnostic rate greater than 85% without the use of ROSE, the diagnostic adequacy only increased by 5% with ROSE implementation (RR = 1.05, 95% CI = 1.03-1.06). CONCLUSIONS The use of ROSE during first-time FNA of thyroid nodules can significantly improve adequacy, especially at institutions with baseline high inadequacy rates. Implementation of ROSE can reduce repeat FNAs and its associated consequences.
Collapse
Affiliation(s)
- Peter P Issa
- Department of Surgery, Tulane University School of Medicine, New Orleans, Louisiana; Louisiana State University Health Sciences Center School of Medicine, New Orleans, Louisiana
| | | | - Mohammad Hussein
- Department of Surgery, Tulane University School of Medicine, New Orleans, Louisiana
| | - Aaron L Albuck
- Louisiana State University Health Sciences Center School of Medicine, New Orleans, Louisiana
| | - Essam Emad
- Department of Surgery, Tulane University School of Medicine, New Orleans, Louisiana
| | - Mohamed Shama
- Department of Surgery, Tulane University School of Medicine, New Orleans, Louisiana
| | - Krzysztof Moroz
- Department of Pathology and Laboratory Medicine, Tulane University School of Medicine, New Orleans, Louisiana
| | - Eman Toraih
- Department of Surgery, Tulane University School of Medicine, New Orleans, Louisiana; Genetics Unit, Department of Histology and Cell Biology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt
| | - Emad Kandil
- Department of Surgery, Tulane University School of Medicine, New Orleans, Louisiana.
| |
Collapse
|
4
|
Toraih E, Hussein M, Anker A, Baah S, Pinion D, Jishu J, Sadakkadulla S, Case M, LaForteza A, Moroz K, Kandil E. Survival Outcomes of Medullary Thyroid Cancer With and Without Amyloid Deposition. Endocr Pract 2024; 30:311-318. [PMID: 38184237 DOI: 10.1016/j.eprac.2024.01.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/14/2023] [Revised: 12/22/2023] [Accepted: 01/02/2024] [Indexed: 01/08/2024]
Abstract
OBJECTIVE Amyloid deposition within tumor stroma is a distinctive histologic feature of medullary thyroid cancer (MTC). However, its prognostic significance remains uncertain. We aimed to elucidate the impact of amyloid status on survival outcomes in a large cohort. METHODS The Surveillance, Epidemiology, and End Results registry was queried to identify patients diagnosed with MTC from 2000 to 2019. Patients with amyloid-positive (International Classification of Diseases for Oncology, third edition code 8345/3) and amyloid negative (International Classification of Diseases for Oncology, third edition code 8510/3) tumors were analyzed. Overall and disease-specific survival were compared between matched cohorts using Kaplan-Meier and Cox proportional hazards analyses. RESULTS Of the 2526 MTC patients, 511 of which were amyloid-positive and 2015 that were amyloid negative. Amyloid-positive patients displayed lower T stage (T3/4: 28% vs 85%, P < .001) and less extrathyroidal extension (11.3% vs 81.6%, P < .001). No difference in distant metastasis rate was observed between groups (14.5% vs 14.4%, P = .98). However, amyloid-positive patients showed a tendency for distal lymph node metastasis (1.2% vs 0.3%, P = .020). On univariate analysis, amyloid-positive status showed comparable overall survival times (mean 172.2 vs 177.8 months, P = .17), but a trend toward worse cancer-specific survival (hazard ratios [HR] = 1.31, 95% CI = 0.99-1.71, P = .051). After adjusting for covariates, amyloid deposition did not independently predict overall (HR = 1.15, 95% CI = 0.91-1.47, P = .25) or cancer-specific survival (HR = 1.30, 95% CI = 0.96-1.77, P = .09). Initiating therapy later than 1 month following diagnosis was associated with worse overall survival (HR = 1.25, 95% CI = 1.02-1.54, P = .029). CONCLUSIONS The presence of amyloid in MTC paradoxically associates with lower T stage yet exhibits a trend toward worse cancer-specific mortality. Amyloid deposition alone does not independently influence prognosis. Delayed treatment adversely impacted overall survival.
Collapse
Affiliation(s)
- Eman Toraih
- Division of Endocrine and Oncologic Surgery, Department of Surgery, School of Medicine, Tulane University, New Orleans, Louisiana; Genetics Unit, Department of Histology and Cell Biology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.
| | - Mohammad Hussein
- Division of Endocrine and Oncologic Surgery, Department of Surgery, School of Medicine, Tulane University, New Orleans, Louisiana
| | - Allison Anker
- School of Medicine, Tulane University, New Orleans, Louisiana
| | - Solomon Baah
- School of Medicine, Tulane University, New Orleans, Louisiana
| | - Dylan Pinion
- School of Medicine, Tulane University, New Orleans, Louisiana
| | - Jessan Jishu
- School of Medicine, Tulane University, New Orleans, Louisiana
| | | | - Madeline Case
- School of Medicine, Tulane University, New Orleans, Louisiana
| | | | - Krzysztof Moroz
- Department of Pathology and Laboratory Medicine, School of Medicine, Tulane University, New Orleans, Louisiana
| | - Emad Kandil
- Division of Endocrine and Oncologic Surgery, Department of Surgery, School of Medicine, Tulane University, New Orleans, Louisiana
| |
Collapse
|
5
|
Botnariuc D, Court S, Lourenço A, Gosling A, Royle G, Hussein M, Rompokos V, Veiga C. Evaluation of monte carlo to support commissioning of the treatment planning system of new pencil beam scanning proton therapy facilities. Phys Med Biol 2024; 69:045027. [PMID: 38052092 DOI: 10.1088/1361-6560/ad1272] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2023] [Accepted: 12/05/2023] [Indexed: 12/07/2023]
Abstract
Objective. To demonstrate the potential of Monte Carlo (MC) to support the resource-intensive measurements that comprise the commissioning of the treatment planning system (TPS) of new proton therapy facilities.Approach. Beam models of a pencil beam scanning system (Varian ProBeam) were developed in GATE (v8.2), Eclipse proton convolution superposition algorithm (v16.1, Varian Medical Systems) and RayStation MC (v12.0.100.0, RaySearch Laboratories), using the beam commissioning data. All models were first benchmarked against the same commissioning data and validated on seven spread-out Bragg peak (SOBP) plans. Then, we explored the use of MC to optimise dose calculation parameters, fully understand the performance and limitations of TPS in homogeneous fields and support the development of patient-specific quality assurance (PSQA) processes. We compared the dose calculations of the TPSs against measurements (DDTPSvs.Meas.) or GATE (DDTPSvs.GATE) for an extensive set of plans of varying complexity. This included homogeneous plans with varying field-size, range, width, and range-shifters (RSs) (n= 46) and PSQA plans for different anatomical sites (n= 11).Main results. The three beam models showed good agreement against the commissioning data, and dose differences of 3.5% and 5% were found for SOBP plans without and with RSs, respectively. DDTPSvs.Meas.and DDTPSvs.GATEwere correlated in most scenarios. In homogeneous fields the Pearson's correlation coefficient was 0.92 and 0.68 for Eclipse and RayStation, respectively. The standard deviation of the differences between GATE and measurements (±0.5% for homogeneous and ±0.8% for PSQA plans) was applied as tolerance when comparing TPSs with GATE. 72% and 60% of the plans were within the GATE predicted dose difference for both TPSs, for homogeneous and PSQA cases, respectively.Significance. Developing and validating a MC beam model early on into the commissioning of new proton therapy facilities can support the validation of the TPS and facilitate comprehensive investigation of its capabilities and limitations.
Collapse
Affiliation(s)
- D Botnariuc
- Department of Medical Physics and Biomedical Engineering, University College London, Gower Street, London, WC1E 6BT, United Kingdom
- Metrology for Medical Physics Centre, National Physical Laboratory, Hampton Road, Teddington, TW11 0LW, United Kingdom
| | - S Court
- Radiotherapy Physics Services, University College London Hospitals NHS Foundation Trust, 250 Euston Road, London, NW1 2PG, United Kingdom
| | - A Lourenço
- Department of Medical Physics and Biomedical Engineering, University College London, Gower Street, London, WC1E 6BT, United Kingdom
- Metrology for Medical Physics Centre, National Physical Laboratory, Hampton Road, Teddington, TW11 0LW, United Kingdom
| | - A Gosling
- Radiotherapy Physics Services, University College London Hospitals NHS Foundation Trust, 250 Euston Road, London, NW1 2PG, United Kingdom
| | - G Royle
- Department of Medical Physics and Biomedical Engineering, University College London, Gower Street, London, WC1E 6BT, United Kingdom
| | - M Hussein
- Metrology for Medical Physics Centre, National Physical Laboratory, Hampton Road, Teddington, TW11 0LW, United Kingdom
| | - V Rompokos
- Radiotherapy Physics Services, University College London Hospitals NHS Foundation Trust, 250 Euston Road, London, NW1 2PG, United Kingdom
| | - C Veiga
- Department of Medical Physics and Biomedical Engineering, University College London, Gower Street, London, WC1E 6BT, United Kingdom
| |
Collapse
|
6
|
Cironi K, Albuck AL, McLafferty B, Mortemore AK, McCarthy C, Hussein M, Issa PP, Metz T, Herrera M, Toraih E, Taghavi S, Kandil E, Turner J. Risk Factors for Postoperative Infections Following Appendectomy of Complicated Appendicitis: A Meta-analysis and Retrospective Single-institutional Study. Surg Laparosc Endosc Percutan Tech 2024; 34:20-28. [PMID: 37852230 DOI: 10.1097/sle.0000000000001234] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2023] [Accepted: 08/22/2023] [Indexed: 10/20/2023]
Abstract
Patients with complicated appendicitis have an increased risk for postoperative infections. Potential risk factors for postoperative infections through a meta-analysis and retrospective chart review are discussed. A meta-analysis consisting of 35 studies analyzing complicated appendicitis treated with an appendectomy noting at least 1 postoperative infection was performed. A retrospective review was then conducted in patients diagnosed with complicated appendicitis after appendectomy. Of 5326 patients in total, 15.4% developed postoperative infections. Laparoscopic surgery and perioperative hyperoxygenation were found to be protective factors for the development of infection. Retrospectively, 53.2% of patients presented with complicated appendicitis. Patients with complicated appendicitis were more likely to be older in age and have an increased length of stay. Patient demographics, operative time, and comorbid status had no effect on postoperative infection or readmission rate. Physicians should strongly consider minimally invasive techniques to treat all cases of complicated appendicitis irrespective of comorbidities, age, sex, or body mass index.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Peter P Issa
- Louisiana State University Health Sciences Center School of Medicine, New Orleans, LA
| | | | | | - Eman Toraih
- Department of Surgery, Division of Endocrine and Oncologic Surgery
- Department of Genetics, Histology and Cell Biology, Suez Canal University Faculty of Medicine, Ismailia, Egypt
| | - Sharven Taghavi
- Department of Surgery, Division of Trauma and Critical Care, Tulane University School of Medicine
| | - Emad Kandil
- Department of Surgery, Division of Endocrine and Oncologic Surgery
| | - Jacquelyn Turner
- Department of Surgery, Division of Endocrine and Oncologic Surgery
| |
Collapse
|
7
|
Hussein M, Toraih E, Issa PP, Omar M, Aboueisha M, Buti Y, Issa CP, Albuck AL, Cironi K, Attia AS, LaForteza AC, Shama M, Kandil E. From ablation to operation: Unraveling the surgical outcomes and complications of thyroidectomy after radiofrequency ablation. Surgery 2024; 175:146-152. [PMID: 37867100 DOI: 10.1016/j.surg.2023.09.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2023] [Revised: 08/21/2023] [Accepted: 09/05/2023] [Indexed: 10/24/2023]
Abstract
BACKGROUND Radiofrequency ablation is a minimally invasive treatment for thyroid nodules; however, concerns exist regarding its impact on subsequent thyroid surgery. We compared surgical outcomes and complications between patients undergoing thyroidectomy after radiofrequency ablation (post-radiofrequency ablation thyroidectomy group) and those without prior radiofrequency ablation (non-radiofrequency ablation thyroidectomy group). METHODS We retrospectively analyzed thyroidectomy patients, comparing post-radiofrequency ablation thyroidectomy and non-radiofrequency ablation thyroidectomy groups, examining demographics, nodule characteristics, surgical techniques, and complications. RESULTS The study included 96 patients (73 in the non-radiofrequency ablation thyroidectomy group and 23 in the post-radiofrequency ablation thyroidectomy group). The mean age was 53.3 ± 14.4 years, with 78.1% female patients and 36.5% African American patients. Median operative time was similar between the post-radiofrequency ablation thyroidectomy (110 minutes) and the non-radiofrequency ablation thyroidectomy (92 minutes) cohorts (P = .40). Complications were reported in 13 patients, without significant differences between groups (P = .54). No permanent complications, including nerve injury or hypoparathyroidism, were reported in either cohort. Prior radiofrequency ablation treatment did not increase the risk of complications (odds ratio = 3.48, 95% confidence interval = 0.70-17.43, P = .16). CONCLUSION Our work found no differences in outcomes or safety in patients undergoing thyroidectomy with or without previous radiofrequency ablation treatment, potentiating the post-radiofrequency ablation thyroidectomy group as a safe management option. Accordingly, this may reassure both clinicians and patients of the safety of radiofrequency ablation in treating patients with thyroid nodules.
Collapse
Affiliation(s)
- Mohammad Hussein
- Department of Surgery, Tulane University, School of Medicine, New Orleans, LA
| | - Eman Toraih
- Department of Surgery, Tulane University, School of Medicine, New Orleans, LA.
| | - Peter P Issa
- Department of Surgery, Tulane University, School of Medicine, New Orleans, LA
| | - Mahmoud Omar
- Department of Surgery, Tulane University, School of Medicine, New Orleans, LA
| | - Mohamed Aboueisha
- Department of Surgery, Tulane University, School of Medicine, New Orleans, LA
| | - Yusef Buti
- Department of Surgery, Tulane University, School of Medicine, New Orleans, LA
| | - Chad P Issa
- Department of Surgery, Tulane University, School of Medicine, New Orleans, LA
| | - Aaron L Albuck
- Department of Surgery, Tulane University, School of Medicine, New Orleans, LA
| | - Katherine Cironi
- Department of Surgery, Tulane University, School of Medicine, New Orleans, LA
| | - Abdallah S Attia
- Department of Surgery, Tulane University, School of Medicine, New Orleans, LA
| | | | - Mohamed Shama
- Department of Surgery, Tulane University, School of Medicine, New Orleans, LA
| | - Emad Kandil
- Department of Surgery, Tulane University, School of Medicine, New Orleans, LA
| |
Collapse
|
8
|
Issa PP, Hossam E, Cheng JH, Magazine BM, Hussein M, Luo X, Abdelhady A, Staav J, LaForteza A, Albuck AL, Shama M, Toraih E, Kandil E. Completion thyroidectomy: A safe option for high-volume surgeons. Head Neck 2024; 46:57-63. [PMID: 37872858 DOI: 10.1002/hed.27551] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2023] [Revised: 08/10/2023] [Accepted: 10/09/2023] [Indexed: 10/25/2023] Open
Abstract
BACKGROUND The risk of complication in patients undergoing completion thyroidectomy (cT) is mixed. Several studies report increased risk in comparison to total thyroidectomy (TT) and still others reporting a comparatively decreased risk. We compared the rates of complication in patients at our institution undergoing thyroid lobectomy (TL), (TT), and cT by a single high-volume surgeon. METHODS We performed a single-institution retrospective cohort study. Patients undergoing TL, TT, or cT by a high-volume surgeon were included. Rates of complication were collected and compared between the three cohorts. RESULTS A total of 310 patients were included. The overall rate of complication was 4.2%. The complication rates in the TL, TT, and cT cohorts were 1%, 7.1%, and 4.5%, respectively (p = 0.10). Transient hypocalcemia was slightly more common in the TT cohort (6.1%) as opposed to the TL (0%) or cT (0.9%) cohort (p = 0.01). The cohorts also had similar rates of recurrent laryngeal nerve signal loss leading to transient dysphonia (TL: 0% vs. TT: 1% vs. cT: 3.6%, p = 0.10). CONCLUSIONS While rates of complication tended to predictably decrease as approaches became less extensive, there were no significant differences in complication rates among the three surgical approaches when performed by a high-volume surgeon. Considering the low rates of complication overall, patient counseling and preference should be emphasized to provide appropriate and tailored treatment plans.
Collapse
Affiliation(s)
- Peter P Issa
- Department of Surgery, Tulane University School of Medicine, New Orleans, Louisiana, USA
| | - Eslam Hossam
- Department of Surgery, Tulane University School of Medicine, New Orleans, Louisiana, USA
| | - Jack H Cheng
- Department of Surgery, Tulane University School of Medicine, New Orleans, Louisiana, USA
| | - Brandon M Magazine
- Department of Surgery, Tulane University School of Medicine, New Orleans, Louisiana, USA
| | - Mohammad Hussein
- Department of Surgery, Tulane University School of Medicine, New Orleans, Louisiana, USA
| | - Xinyi Luo
- Department of Surgery, Tulane University School of Medicine, New Orleans, Louisiana, USA
| | - Ali Abdelhady
- Department of Surgery, Tulane University School of Medicine, New Orleans, Louisiana, USA
| | - Jonathan Staav
- Department of Surgery, Tulane University School of Medicine, New Orleans, Louisiana, USA
| | - Alexandra LaForteza
- Department of Surgery, Tulane University School of Medicine, New Orleans, Louisiana, USA
| | - Aaron L Albuck
- Department of Surgery, Tulane University School of Medicine, New Orleans, Louisiana, USA
| | - Mohamed Shama
- Department of Surgery, Tulane University School of Medicine, New Orleans, Louisiana, USA
| | - Eman Toraih
- Department of Surgery, Tulane University School of Medicine, New Orleans, Louisiana, USA
| | - Emad Kandil
- Department of Surgery, Tulane University School of Medicine, New Orleans, Louisiana, USA
| |
Collapse
|
9
|
Russell JO, Desai DD, Noel JE, Hussein M, Toraih E, Seo S, Wolfe S, Omar M, Issa P, Orloff LA, Tufano RP, Kandil E. Radiofrequency ablation of benign thyroid nodules: A prospective, multi-institutional North American experience. Surgery 2024; 175:139-145. [PMID: 37953141 DOI: 10.1016/j.surg.2023.07.046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2023] [Revised: 05/18/2023] [Accepted: 07/08/2023] [Indexed: 11/14/2023]
Abstract
BACKGROUND Radiofrequency ablation for benign thyroid nodules aims to achieve a volume reduction rate of ≥50%. However, factors that predict treatment success have not been defined in a large-scale study. METHODS A prospective cohort study of biopsy-proven benign thyroid nodules treated with radiofrequency ablation at 3 institutions was performed. Patient demographics, nodule sonographic features, procedural data, and nodule volume reduction were evaluated. Binary logistic regression analysis was performed to identify features associated with treatment response. RESULTS A total of 620 nodules were analyzed. The pooled median volume reduction rate at 12 months was 70.9% (interquartile range 52.9-86.6). At 1 year follow-up, 78.4% of nodules reached treatment success with a volume reduction rate ≥50%. The overall complication rate was 3.2% and included temporary voice changes (n = 14), vasovagal episodes (n = 5), nodule rupture (n = 3), and lightheadedness (n = 2). No permanent voice changes occurred. Four patients developed postprocedural hypothyroidism. Large baseline nodule volume (>20 mL) was associated with a lower rate of successful volume reduction (odds ratio 0.60 [0.37-0.976]). Large nodules achieved treatment success by 12-month follow-up at a rate of 64.5%, compared with 81.4% for small nodules and 87.2% for medium nodules. CONCLUSION To our knowledge, this is the largest North American cohort of patients with benign thyroid nodules treated with radiofrequency ablation. Overall, radiofrequency ablation was an effective treatment option with a low risk of procedural complications. Large volume nodules (>20 mL) may be associated with a lower rate of successful reduction with radiofrequency ablation treatment.
Collapse
Affiliation(s)
- Jonathon O Russell
- Department of Otolaryngology-Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD
| | - Dipan D Desai
- Department of Otolaryngology-Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD
| | - Julia E Noel
- Department of Otolaryngology-Head & Neck Surgery, Stanford University School of Medicine, Palo Alto, CA.
| | - Mohammad Hussein
- Division of Endocrine and Oncologic Surgery, Department of Surgery, Tulane University School of Medicine, New Orleans, LA
| | - Eman Toraih
- Division of Endocrine and Oncologic Surgery, Department of Surgery, Tulane University School of Medicine, New Orleans, LA; Genetics Unit, Department of Histology and Cell Biology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt
| | - Stefanie Seo
- Department of Otolaryngology-Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD
| | - Samantha Wolfe
- Section of Endocrine Surgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada
| | - Mahmoud Omar
- Division of Endocrine and Oncologic Surgery, Department of Surgery, Tulane University School of Medicine, New Orleans, LA
| | - Peter Issa
- Division of Endocrine and Oncologic Surgery, Department of Surgery, Tulane University School of Medicine, New Orleans, LA
| | - Lisa A Orloff
- Department of Otolaryngology-Head & Neck Surgery, Stanford University School of Medicine, Palo Alto, CA
| | - Ralph P Tufano
- Sarasota Memorial Health Care System, FPG Thyroid and Parathyroid Center, Sarasota, FL
| | - Emad Kandil
- Division of Endocrine and Oncologic Surgery, Department of Surgery, Tulane University School of Medicine, New Orleans, LA
| |
Collapse
|
10
|
Hussein M, Angerud A, Saez J, Bogaert E, Lemire M, Barry M, Silvestre Patallo I, Shipley D, Clark CH, Hernandez V. Improving the modelling of a multi-leaf collimator with tilted leaf sides used in radiotherapy. Phys Imaging Radiat Oncol 2024; 29:100543. [PMID: 38390588 PMCID: PMC10881418 DOI: 10.1016/j.phro.2024.100543] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2023] [Revised: 01/24/2024] [Accepted: 01/25/2024] [Indexed: 02/24/2024] Open
Abstract
Background and purpose Multi-leaf collimators (MLCs) with tilted leaf sides have a complex transmission behaviour that is not easily matched by radiotherapy treatment planning systems (TPSs). We sought to develop an MLC model that can accurately match test fields and clinically relevant plans at different centres. Materials and methods Two new MLC models were developed and evaluated within a research version of a commercial TPS. Prototype I used adjusted-constant transmissions and Prototype II used variable transmissions at the tongue-and-groove and leaf-tip regions. Three different centres evaluated these prototypes for a tilted MLC and compared them with their initial MLC model using test fields and patient-specific quality-assurance measurements of clinically relevant plans. For the latter, gamma passing rates (GPR) at 2 %/2mm were recorded. Results For the prototypes the same set of MLC parameters could be used at all centres, with only a slight adjustment of the offset parameter. For centres A and C, average GPR were >95 % and within 0.5 % GPR difference between the standard, and prototype models. In center B, prototypes I and II improved the agreement in clinically relevant plans, with an increase in GPR of 2.3 % ± 0.8 % and 3.0 ± 0.8 %, respectively. Conclusions The prototype MLC models were either similar or superior to the initial MLC model, and simpler to configure because fewer trade-offs were required. Prototype I performed comparably to the more sophisticated Prototype II and its configuration can be easily standardized, which can be useful to reduce variability and improve safety in clinical practice.
Collapse
Affiliation(s)
- Mohammad Hussein
- Metrology for Medical Physics Centre, National Physical Laboratory, Teddington, UK
| | | | - Jordi Saez
- Department of Radiation Oncology, Hospital Clínic de Barcelona, Barcelona, Spain
| | - Evelien Bogaert
- Department of Radiation Oncology, Ghent University Hospital, Belgium
| | | | - Miriam Barry
- Metrology for Medical Physics Centre, National Physical Laboratory, Teddington, UK
| | | | - David Shipley
- Metrology for Medical Physics Centre, National Physical Laboratory, Teddington, UK
| | - Catharine H Clark
- Metrology for Medical Physics Centre, National Physical Laboratory, Teddington, UK
- Medical Physics, University College London Hospital, London, UK
- Medical Physics and Bioengineering, University College London, London, UK
| | - Victor Hernandez
- Department of Medical Physics, Hospital Sant Joan de Reus, IISPV, Tarragona, Spain
- Universitat Rovira i Virgili, Tarragona, Spain
| |
Collapse
|
11
|
Nenoff L, Amstutz F, Murr M, Archibald-Heeren B, Fusella M, Hussein M, Lechner W, Zhang Y, Sharp G, Vasquez Osorio E. Review and recommendations on deformable image registration uncertainties for radiotherapy applications. Phys Med Biol 2023; 68:24TR01. [PMID: 37972540 PMCID: PMC10725576 DOI: 10.1088/1361-6560/ad0d8a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2023] [Revised: 10/30/2023] [Accepted: 11/15/2023] [Indexed: 11/19/2023]
Abstract
Deformable image registration (DIR) is a versatile tool used in many applications in radiotherapy (RT). DIR algorithms have been implemented in many commercial treatment planning systems providing accessible and easy-to-use solutions. However, the geometric uncertainty of DIR can be large and difficult to quantify, resulting in barriers to clinical practice. Currently, there is no agreement in the RT community on how to quantify these uncertainties and determine thresholds that distinguish a good DIR result from a poor one. This review summarises the current literature on sources of DIR uncertainties and their impact on RT applications. Recommendations are provided on how to handle these uncertainties for patient-specific use, commissioning, and research. Recommendations are also provided for developers and vendors to help users to understand DIR uncertainties and make the application of DIR in RT safer and more reliable.
Collapse
Affiliation(s)
- Lena Nenoff
- Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, United States of America
- Harvard Medical School, Boston, MA, United States of America
- OncoRay—National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden—Rossendorf, Dresden Germany
- Helmholtz-Zentrum Dresden—Rossendorf, Institute of Radiooncology—OncoRay, Dresden, Germany
| | - Florian Amstutz
- Department of Physics, ETH Zurich, Switzerland
- Center for Proton Therapy, Paul Scherrer Institute, Villigen PSI, Switzerland
- Division of Medical Radiation Physics and Department of Radiation Oncology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland
| | - Martina Murr
- Section for Biomedical Physics, Department of Radiation Oncology, University of Tübingen, Germany
| | | | - Marco Fusella
- Department of Radiation Oncology, Abano Terme Hospital, Italy
| | - Mohammad Hussein
- Metrology for Medical Physics, National Physical Laboratory, Teddington, United Kingdom
| | - Wolfgang Lechner
- Department of Radiation Oncology, Medical University of Vienna, Austria
| | - Ye Zhang
- Center for Proton Therapy, Paul Scherrer Institute, Villigen PSI, Switzerland
| | - Greg Sharp
- Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, United States of America
- Harvard Medical School, Boston, MA, United States of America
| | - Eliana Vasquez Osorio
- Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom
| |
Collapse
|
12
|
Hussein M, Ali M, Abdelghaffar M, Yassien A, Gomaa R, Assad R, Magdy R. Frequency, characteristics, and predictors of headache attributed to acute ischemic stroke. Rev Neurol (Paris) 2023; 179:1000-1007. [PMID: 37541931 DOI: 10.1016/j.neurol.2023.03.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2022] [Revised: 01/09/2023] [Accepted: 03/05/2023] [Indexed: 08/06/2023]
Abstract
OBJECTIVES Although headache is a common symptom in acute ischemic stroke, the clinical and radiological factors associated with its occurrence are controversial. This work aimed to determine the frequency, characteristics, and predictors of headache occurrence among patients with acute ischemic stroke. METHODS This cross-sectional study was conducted on 303 patients with acute ischemic stroke. The patients were submitted to detailed history taking, clinical and radiological assessment. A detailed analysis of headache was performed for the patients who experienced headache temporally related to stroke onset. RESULTS Diagnosis of headache attributed to the ischemic stroke was established in 129 (42.6%) patients; sentinel headache in 17.2% of patients, and headache at stroke onset in 25.4% of patients. The headache group had a significantly younger age (P=0.017), lower NIHSS score (P=0.042), higher frequency of pre-existing headache disorders (P=0.001), substance use disorder (P=0.021), and fever (P=0.036), and lower frequency of chronic hypertension (P=0.013) and small vessel disease (P=0.004) than non-headache group. Infarction involving posterior circulation was more frequent in headache than in non-headache groups (P=0.003). The presence of migraine, tension-type headache, other types of headache, fever and posterior circulation stroke increased the odds of headache by 27.4 (95%CI=8.0-94.4), 7.6 (95%CI=3.93-14.6), 26.2 (95%CI=8.0-85.8), 3.75 (95%CI=1.22-11.6) and 3.15 (95%CI=1.65-6.0) times, respectively, whereas, the presence of small vessel disease decreased the odds of headache by 0.51 (95%CI=0.279-0.95) times. CONCLUSION Pre-existing headache disorder, fever, and posterior circulation stroke were associated with headache occurrence in acute ischemic stroke patients.
Collapse
Affiliation(s)
- M Hussein
- Department of Neurology, Beni-Suef University, Beni-Suef. Egypt.
| | - M Ali
- Department of Neurology, Beni-Suef University, Beni-Suef. Egypt.
| | - M Abdelghaffar
- Department of Neurology, Fayoum University, Fayoum, Egypt.
| | - A Yassien
- Department of Critical care medicine, Beni-suef University, Beni-Suef. Egypt.
| | - R Gomaa
- Department of Neurology, Beni-Suef University, Beni-Suef. Egypt.
| | - R Assad
- Department of Radiology, Cairo University, Cairo, Egypt.
| | - R Magdy
- Department of Neurology, Cairo University, Cairo, Egypt.
| |
Collapse
|
13
|
Issa PP, Munshi R, Albuck AL, Omar M, Abu Alhuda RF, Metz T, Hussein M, Shama M, Lee GS, Toraih E, Kandil E. Recommend with caution: A meta-analysis investigating papillary thyroid carcinoma tumor progression under active surveillance. Am J Otolaryngol 2023; 44:103994. [PMID: 37607459 DOI: 10.1016/j.amjoto.2023.103994] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2023] [Accepted: 07/08/2023] [Indexed: 08/24/2023]
Abstract
BACKGROUND Papillary thyroid carcinoma (PTC) is an indolent disease with favorable outcomes. The non-surgical treatment approach known as active surveillance (AS) has been introduced as an alternative treatment instead of the traditional thyroidectomy. However, 10-15 % of PTC tend to progress. We sought to determine factors predicting the progression of PTC under AS. METHODS A systematic search was performed in January 2022 using PubMed, Embase, Google Scholar, Web of Science, and ScienceDirect. PRISMA guidelines were used by multiple reviewers to extract study characteristics (author name, publication date, journal name, country, institution, and study design), as well as main outcomes and measures. A combination of utilization of thyroid replacement therapy, baseline tumor size and volume, follow-up tumor size and volume, and the presence of lymph node metastasis and its distribution, as well as surveillance duration, were the main measures of this study. RESULTS Nine studies with 4166 patients were included, of which 354 showed tumor progression during AS (15 %; 95%CI = 7 % - 23 %). The average follow-up period was 41.58 months. The mean tumor maximum diameter was 8.54 mm (95%CI = 7.04-10.03). Tumor progression was most commonly secondary to an increase in volume by ≥50 % (75 %; 95%CI = 68 % - 80 %), then increase in diameter by ≥3 mm (41 %; 95%CI = 13 % - 76 %), and finally the development of lymph node metastasis (13 %; 95%CI = 9 % - 19 %). Approximately only 2 % of all patients thus developed new lymph node metastasis. Patient age, sex, and tumor size were not associated with higher risks of tumor progression. 12 % of AS patients eventually underwent surgery, though only 40 % (95%CI = 27 % - 53 %) of these patients displayed tumor progression. CONCLUSIONS Our meta-analysis determined a tumor progression rate of 15 % in patients who underwent AS management, 13 % of which (2 % of all patients) developed lymph node metastasis. We found no protective or risk factors for tumor progression, and that almost half of all patients who underwent delayed surgery did so for reasons other than tumor progression. While not biopsying small (<1 cm) or very low suspicious nodules is already recommended, AS may be an appropriate treatment option in patients appropriately counseled, considering the low risk of advanced tumor progression but also the considerable patient population who fail to adhere to treatment. Alternatively, in aim of preventing overtreatment in patients who would rather take proactive measures against their low-risk carcinoma, minimally-invasive ablation techniques may be an attractive option.
Collapse
Affiliation(s)
- Peter P Issa
- Department of Surgery, Tulane University School of Medicine, New Orleans, LA, United States of America; School of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA, United States of America
| | - Ruhul Munshi
- Department of Surgery, Tulane University School of Medicine, New Orleans, LA, United States of America
| | - Aaron L Albuck
- School of Medicine, Tulane University, New Orleans, LA, United States of America
| | - Mahmoud Omar
- Department of Surgery, Yale University School of Medicine, New Haven, CT, United States of America
| | - Ruba F Abu Alhuda
- Department of Surgery, Tulane University School of Medicine, New Orleans, LA, United States of America
| | - Tyler Metz
- School of Medicine, Tulane University, New Orleans, LA, United States of America
| | - Mohammad Hussein
- Department of Surgery, Tulane University School of Medicine, New Orleans, LA, United States of America
| | - Mohamed Shama
- Department of Surgery, Tulane University School of Medicine, New Orleans, LA, United States of America
| | - Grace S Lee
- Department of Surgery, Yale University School of Medicine, New Haven, CT, United States of America
| | - Eman Toraih
- Department of Surgery, Tulane University School of Medicine, New Orleans, LA, United States of America; Genetics Unit, Department of Histology and Cell Biology, Suez Canal University Faculty of Medicine, Ismailia, Egypt
| | - Emad Kandil
- Department of Surgery, Tulane University School of Medicine, New Orleans, LA, United States of America.
| |
Collapse
|
14
|
Albuck AL, Issa PP, Hussein M, Aboueisha M, Attia AS, Omar M, Munshi R, Shama M, Toraih E, Randolph GW, Kandil E. A combination of computed tomography scan and ultrasound provides optimal detection of cervical lymph node metastasis in papillary thyroid carcinomas: A systematic review and meta-analysis. Head Neck 2023; 45:2173-2184. [PMID: 37417426 DOI: 10.1002/hed.27451] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2023] [Revised: 06/20/2023] [Accepted: 06/27/2023] [Indexed: 07/08/2023] Open
Abstract
BACKGROUND Lymph node metastasis (LNM) in patients with papillary thyroid carcinoma (PTC) is common. This meta-analysis assesses the diagnostic accuracy of computed tomography (CT), ultrasound (US), and CT + US in detecting central and lateral LNM. METHODS A systematic review and meta-analysis was performed by searching PubMed, Embase, and Cochrane for studies published up to April 2022. The pooled sensitivity, specificity, and diagnostic odds ratio (DOR) were calculated. The area under the curve (AUC) for summary receiver operating curves (sROC) were compared. RESULTS The study population included 7902 patients with a total of 15 014 lymph nodes. Twenty-four studies analyzed the sensitivity of the overall neck region in which dual CT + US imaging (55.9%) had greater sensitivities (p < 0.001) than either US (48.4%) or CT (50.4%) alone. The specificity of US alone (89.0%) was greater (p < 0.001) than CT alone (88.5%) or dual imaging (86.8%). The DOR for dual CT + US imaging was greatest (p < 0.001) at 11.134, while the AUCs of the three imaging modalities were similar (p > 0.05). Twenty-one studies analyzed the sensitivity of the central neck region in which both CT (45.8%) and CT + US imaging (43.4%) had greater sensitivities (p < 0.001) than US alone (35.3%). The specificity of all three modalities was higher than 85%. The DOR for CT (7.985) was greater than US alone (4.723, p < 0.001) or dual CT + US imaging (4.907, p = 0.015). The AUC of both CT + US (0.785) and CT alone (0.785) were significantly greater (p < 0.001) than US alone (0.685). Of the 19 studies that reported lateral LNM, CT + US imaging sensitivity (84.5%) was higher than CT alone (69.2%, p < 0.001) and US alone (79.7%, p = 0.038). The specificity of all imaging techniques was all greater than 80.0%. CT + US imaging DOR (35.573) was greater than CT (20.959, p = 0.024) and US (15.181, p < 0.001) individually. The AUC of independent imaging was high (CT: 0.863, US: 0.858) and improved significantly when combined (CT + US: 0.919, p = 0.024 and p < 0.001, respectively). CONCLUSIONS We report an up-to-date analysis elucidating the diagnostic accuracy of LNM detection by either CT, US, or in combination. Our work suggests dual CT + US to be the best for overall detection of LNM and CT to be preferable in detecting central LNM. The use of either CT or US alone may detect lateral LNM with acceptable accuracy, yet dual imaging (CT + US) significantly improved detection rates.
Collapse
Affiliation(s)
- Aaron L Albuck
- School of Medicine, Tulane University, New Orleans, Louisiana, USA
| | - Peter P Issa
- School of Medicine, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA
- Department of Surgery, Tulane University School of Medicine, New Orleans, Louisiana, USA
| | - Mohammad Hussein
- Department of Surgery, Tulane University School of Medicine, New Orleans, Louisiana, USA
| | - Mohamed Aboueisha
- Department of Surgery, Tulane University School of Medicine, New Orleans, Louisiana, USA
| | - Abdallah S Attia
- Department of Surgery, Tulane University School of Medicine, New Orleans, Louisiana, USA
| | - Mahmoud Omar
- Department of Surgery, Tulane University School of Medicine, New Orleans, Louisiana, USA
| | - Ruhul Munshi
- Department of Surgery, Tulane University School of Medicine, New Orleans, Louisiana, USA
| | - Mohamed Shama
- Department of Surgery, Tulane University School of Medicine, New Orleans, Louisiana, USA
| | - Eman Toraih
- Department of Surgery, Tulane University School of Medicine, New Orleans, Louisiana, USA
- Genetics Unit, Department of Histology and Cell Biology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt
| | - Gregory W Randolph
- Department of Otolaryngology - Head and Neck Surgery, Harvard Medical School, Massachusetts Eye and Ear, Boston, Massachusetts, USA
| | - Emad Kandil
- Department of Surgery, Tulane University School of Medicine, New Orleans, Louisiana, USA
| |
Collapse
|
15
|
Saez J, Bar-Deroma R, Bogaert E, Cayez R, Chow T, Clark CH, Esposito M, Feygelman V, Monti AF, Garcia-Miguel J, Gershkevitsh E, Goossens J, Herrero C, Hussein M, Khamphan C, Kierkels RGJ, Lechner W, Lemire M, Nevelsky A, Nguyen D, Paganini L, Pasler M, Fernando Pérez Azorín J, Ramos Garcia LI, Russo S, Shakeshaft J, Vieillevigne L, Hernandez V. Universal evaluation of MLC models in treatment planning systems based on a common set of dynamic tests. Radiother Oncol 2023; 186:109775. [PMID: 37385376 DOI: 10.1016/j.radonc.2023.109775] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2023] [Revised: 06/19/2023] [Accepted: 06/23/2023] [Indexed: 07/01/2023]
Abstract
PURPOSE To demonstrate the feasibility of characterising MLCs and MLC models implemented in TPSs using a common set of dynamic beams. MATERIALS AND METHODS A set of tests containing synchronous (SG) and asynchronous sweeping gaps (aSG) was distributed among twenty-five participating centres. Doses were measured with a Farmer-type ion chamber and computed in TPSs, which provided a dosimetric characterisation of the leaf tip, tongue-and-groove, and MLC transmission of each MLC, as well as an assessment of the MLC model in each TPS. Five MLC types and four TPSs were evaluated, covering the most frequent combinations used in radiotherapy departments. RESULTS Measured differences within each MLC type were minimal, while large differences were found between MLC models implemented in clinical TPSs. This resulted in some concerning discrepancies, especially for the HD120 and Agility MLCs, for which differences between measured and calculated doses for some MLC-TPS combinations exceeded 10%. These large differences were particularly evident for small gap sizes (5 and 10 mm), as well as for larger gaps in the presence of tongue-and-groove effects. A much better agreement was found for the Millennium120 and Halcyon MLCs, differences being within ± 5% and ± 2.5%, respectively. CONCLUSIONS The feasibility of using a common set of tests to assess MLC models in TPSs was demonstrated. Measurements within MLC types were very similar, but TPS dose calculations showed large variations. Standardisation of the MLC configuration in TPSs is necessary. The proposed procedure can be readily applied in radiotherapy departments and can be a valuable tool in IMRT and credentialing audits.
Collapse
Affiliation(s)
- Jordi Saez
- Hospital Clínic de Barcelona, Department of Radiation Oncology, Barcelona, Spain.
| | - Raquel Bar-Deroma
- Rambam Health Care Campus, Department of Radiotherapy, Division of Oncology, Haifa, Israel
| | - Evelien Bogaert
- Ghent University Hospital and Ghent University, Department of Radiation Oncology, Ghent, Belgium
| | - Romain Cayez
- Oscar Lambret Center, Department of Medical Physics, Lille, France
| | - Tom Chow
- Juravinski Hospital and Cancer Centre at Hamilton Health Sciences, Department of Medical Physics, Ontario, Canada
| | - Catharine H Clark
- National Physical Laboratory, Metrology for Medical Physics Centre, London TW11 0PX, UK; Radiotherapy Physics, University College London Hospital, 250 Euston Rd, London NW1 2PG, UK; Dept Medical Physics and Bioengineering, University College London, Malet Place, London WC1 6BT, UK
| | - Marco Esposito
- AUSL Toscana Centro, Medical Physics Unit, Florence, Italy; The Abdus Salam International Center for Theoretical, Trieste, Italy
| | | | - Angelo F Monti
- ASST GOM Niguarda, Department of Medical Physics, Milano, Italy
| | - Julia Garcia-Miguel
- Consorci Sanitari de Terrassa, Department of Radiation Oncology, Terrassa, Spain
| | - Eduard Gershkevitsh
- North Estonia Medical Centre, Department of Medical Physics, Tallinn, Estonia
| | - Jo Goossens
- Iridium Netwerk, Department of Medical Physics, Antwerp, Belgium
| | - Carmen Herrero
- Centro Médico de Asturias-IMOMA, Department of Medical Physics, Oviedo, Spain
| | - Mohammad Hussein
- National Physical Laboratory, Metrology for Medical Physics Centre, London TW11 0PX, UK
| | - Catherine Khamphan
- Institut du Cancer - Avignon Provence, Department of Medical Physics, Avignon, France
| | - Roel G J Kierkels
- Radiotherapiegroep, Department of Medical Physics, Arnhem/Deventer, the Netherlands
| | - Wolfgang Lechner
- Medical University of Vienna, Department of Radiation Oncology, Vienna, Austria
| | - Matthieu Lemire
- CIUSSS de l'Est-de-l'Île-de-Montréal, Service de Radio-Physique, Montréal, Canada
| | - Alexander Nevelsky
- Rambam Health Care Campus, Department of Radiotherapy, Division of Oncology, Haifa, Israel
| | | | - Lucia Paganini
- Humanitas Clinical and Research Center, Radiotherapy and Radiosurgery Department, Rozzano, Italy
| | - Marlies Pasler
- Lake Constance Radiation Oncology Center, Department of Radiation Oncology, Singen, Friedrichshafen, Germany; Radiotherapy Hirslanden, St. Gallen, Switzerland
| | - José Fernando Pérez Azorín
- Medical Physics and Radiation Protection Department, Gurutzeta-Cruces University Hospital, Barakaldo, Spain; Biocruces Health Research Institute, Barakaldo, Spain
| | | | | | - John Shakeshaft
- Gold Coast University Hospital, ICON Cancer Centre, Gold Coast, Australia
| | - Laure Vieillevigne
- Institut Claudius Regaud-Institut Universitaire du Cancer de Toulouse, Department of Medical Physics, Toulouse, France
| | - Victor Hernandez
- Hospital Sant Joan de Reus, Department of Medical Physics, Reus, Spain; Universitat Rovira i Virgili, Tarragona, Spain
| |
Collapse
|
16
|
Lourenço A, Lee N, Charlwood F, Lambert J, Vera-Sánchez JA, Hussein M, Shipley D, Romano F, Lowe M, Clarke M, Lorentini S, Mazal A, Pettingell J, Palmans H, Thomas R. A portable primary-standard level graphite calorimeter for absolute dosimetry in clinical pencil beam scanning proton beams. Phys Med Biol 2023; 68:175005. [PMID: 37414003 DOI: 10.1088/1361-6560/ace50f] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2022] [Accepted: 07/06/2023] [Indexed: 07/08/2023]
Abstract
Objective. To report the use of a portable primary standard level graphite calorimeter for direct dose determination in clinical pencil beam scanning proton beams, which forms part of the recommendations of the proposed Institute of Physics and Engineering in Medicine (IPEM) Code of Practice (CoP) for proton therapy dosimetry.Approach. The primary standard proton calorimeter (PSPC) was developed at the National Physical Laboratory (NPL) and measurements were performed at four clinical proton therapy facilities that use pencil beam scanning for beam delivery. Correction factors for the presence of impurities and vacuum gaps were calculated and applied, as well as dose conversion factors to obtain dose to water. Measurements were performed in the middle of 10 × 10 × 10 cm3homogeneous dose volumes, centred at 10.0, 15.0 and 25.0 g·cm-2depth in water. The absorbed dose to water determined with the calorimeter was compared to the dose obtained using PTW Roos-type ionisation chambers calibrated in terms of absorbed dose to water in60Co applying the recommendations in the IAEA TRS-398 CoP.Main results.The relative dose difference between the two protocols varied between 0.4% and 2.1% depending on the facility. The reported overall uncertainty in the determination of absorbed dose to water using the calorimeter is 0.9% (k= 1), which corresponds to a significant reduction of uncertainty in comparison with the TRS-398 CoP (currently with an uncertainty equal or larger than 2.0% (k= 1) for proton beams).Significance. The establishment of a purpose-built primary standard and associated CoP will considerably reduce the uncertainty of the absorbed dose to water determination and ensure improved accuracy and consistency in the dose delivered to patients treated with proton therapy and bring proton reference dosimetry uncertainty in line with megavoltage photon radiotherapy.
Collapse
Affiliation(s)
- A Lourenço
- Medical Radiation Science Group, National Physical Laboratory, Teddington TW11 0LW, United Kingdom
- Department of Medical Physics and Biomedical Engineering, University College London, London WC1E 6BT, United Kingdom
| | - N Lee
- Medical Radiation Science Group, National Physical Laboratory, Teddington TW11 0LW, United Kingdom
| | - F Charlwood
- Christie Medical Physics and Engineering, The Christie NHS Foundation Trust, Manchester M20 4BX, United Kingdom
| | - J Lambert
- Rutherford Cancer Centre South Wales, Newport NP10 8FZ, United Kingdom
| | - J A Vera-Sánchez
- Centro de Protonterapia Quirónsalud, E-28223 Pozuelo de Alarcón, Madrid, Spain
| | - M Hussein
- Medical Radiation Science Group, National Physical Laboratory, Teddington TW11 0LW, United Kingdom
- Department of Medical Physics and Biomedical Engineering, University College London, London WC1E 6BT, United Kingdom
| | - D Shipley
- Medical Radiation Science Group, National Physical Laboratory, Teddington TW11 0LW, United Kingdom
| | - F Romano
- Istituto Nazionale di Fisica Nucleare, Sezione di Catania, Via S Sofia 64, I-95123, Catania, Italy
| | - M Lowe
- Christie Medical Physics and Engineering, The Christie NHS Foundation Trust, Manchester M20 4BX, United Kingdom
| | - M Clarke
- Christie Medical Physics and Engineering, The Christie NHS Foundation Trust, Manchester M20 4BX, United Kingdom
| | - S Lorentini
- Protontherapy Department, Azienda Provinciale per i Servizi Sanitari (APSS), Trento, Italy
| | - A Mazal
- Centro de Protonterapia Quirónsalud, E-28223 Pozuelo de Alarcón, Madrid, Spain
| | - J Pettingell
- Rutherford Cancer Centre North East, Bedlington NE22 7FD, United Kingdom
| | - H Palmans
- Medical Radiation Science Group, National Physical Laboratory, Teddington TW11 0LW, United Kingdom
- Medical Physics Group, MedAustron Ion Therapy Center, A-2700 Wiener Neustadt, Austria
| | - R Thomas
- Medical Radiation Science Group, National Physical Laboratory, Teddington TW11 0LW, United Kingdom
- University of Surrey, Faculty of Engineering and Physical Science, Guildford GU2 7XH, United Kingdom
| |
Collapse
|
17
|
Cironi KA, Issa PP, Albuck AL, McCarthy C, Rezvani L, Hussein M, Luo X, Shama M, Toraih E, Kandil E. Comparison of Medical Management versus Parathyroidectomy in Patients with Mild Primary Hyperparathyroidism: A Meta-Analysis. Cancers (Basel) 2023; 15:3085. [PMID: 37370696 DOI: 10.3390/cancers15123085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2023] [Revised: 06/06/2023] [Accepted: 06/06/2023] [Indexed: 06/29/2023] Open
Abstract
BACKGROUND Parathyroidectomy is the definitive cure for patients with primary hyperparathyroidism (pHPT) and has an annual prevalence of 0.2-1% in the United States. Some patients with mild disease are medically managed effectively using calcium-lowering medications and drugs against complications such as osteoporosis; however, many maintain a persistently high calcium level that negatively impacts their skeletal, renal, and psychogenic systems over the long term. This meta-analysis aims to compare the outcomes of medical management versus parathyroidectomy in patients with mild pHPT. STUDY DESIGN This meta-analysis was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines using PubMed, Embase, and Web of Science by two teams of investigators. Analysis was run using R packages. RESULTS A total of 12 publications including seven randomized control, two prospective, and three retrospective trials with a total of 1346 patients were included for analysis. The average follow-up for all patients was 41 ± 23.8 months. Demographics, pre-treatment calcium, PTH, and bone mineral density (BMD) were similar between the medical (N = 632) and surgical (N = 714) cohorts. Post-treatment calcium and PTH levels were significantly higher in the medical cohort (10.46 vs. 9.39, p < 0.01), (106.14 vs. 43.25, p = 0.001), respectively. Interestingly, the post-treatment PTH in the medical cohort increased when compared to pre-treatment (83.84 to 106.14). Patients in the medical cohort had lower BMD in lumbar (0.48 g/cm2; OR = 0.42, 95% CI = 0.21, 0.83), femoral (0.48; OR = 0.42, 95% CI = 0.29, 0.61), and hip (0.61; OR = 0.33, 95% CI = 0.13, 0.85). Incidences of fracture, nephrolithiasis, cardiovascular death, or overall mortality were not significantly different between the cohorts. CONCLUSIONS The present study is the most comprehensive meta-analysis on mild pHPT to date. Our findings reflect that parathyroidectomy is the superior option in the treatment of mild pHPT patients as opposed to medical management.
Collapse
Affiliation(s)
| | - Peter P Issa
- School of Medicine, Louisiana State University, New Orleans, LA 70112, USA
| | - Aaron L Albuck
- School of Medicine, Tulane University, New Orleans, LA 70112, USA
| | | | - Leely Rezvani
- School of Medicine, Tulane University, New Orleans, LA 70112, USA
| | - Mohammad Hussein
- School of Medicine, Tulane University, New Orleans, LA 70112, USA
| | - Xinyi Luo
- School of Medicine, Tulane University, New Orleans, LA 70112, USA
| | - Mohamed Shama
- School of Medicine, Tulane University, New Orleans, LA 70112, USA
| | - Eman Toraih
- School of Medicine, Tulane University, New Orleans, LA 70112, USA
- Genetics Unit, Department of Histology and Cell Biology, Faculty of Medicine, Suez Canal University, Ismailia 41511, Egypt
| | - Emad Kandil
- School of Medicine, Tulane University, New Orleans, LA 70112, USA
| |
Collapse
|
18
|
Murr M, Brock KK, Fusella M, Hardcastle N, Hussein M, Jameson MG, Wahlstedt I, Yuen J, McClelland JR, Vasquez Osorio E. Applicability and usage of dose mapping/accumulation in radiotherapy. Radiother Oncol 2023; 182:109527. [PMID: 36773825 DOI: 10.1016/j.radonc.2023.109527] [Citation(s) in RCA: 9] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2022] [Revised: 01/26/2023] [Accepted: 02/03/2023] [Indexed: 02/12/2023]
Abstract
Dose mapping/accumulation (DMA) is a topic in radiotherapy (RT) for years, but has not yet found its widespread way into clinical RT routine. During the ESTRO Physics workshop 2021 on "commissioning and quality assurance of deformable image registration (DIR) for current and future RT applications", we built a working group on DMA from which we present the results of our discussions in this article. Our aim in this manuscript is to shed light on the current situation of DMA in RT and to highlight the issues that hinder consciously integrating it into clinical RT routine. As a first outcome of our discussions, we present a scheme where representative RT use cases are positioned, considering expected anatomical variations and the impact of dose mapping uncertainties on patient safety, which we have named the DMA landscape (DMAL). This tool is useful for future reference when DMA applications get closer to clinical day-to-day use. Secondly, we discussed current challenges, lightly touching on first-order effects (related to the impact of DIR uncertainties in dose mapping), and focusing in detail on second-order effects often dismissed in the current literature (as resampling and interpolation, quality assurance considerations, and radiobiological issues). Finally, we developed recommendations, and guidelines for vendors and users. Our main point include: Strive for context-driven DIR (by considering their impact on clinical decisions/judgements) rather than perfect DIR; be conscious of the limitations of the implemented DIR algorithm; and consider when dose mapping (with properly quantified uncertainties) is a better alternative than no mapping.
Collapse
Affiliation(s)
- Martina Murr
- Section for Biomedical Physics, Department of Radiation Oncology, University of Tübingen, Germany.
| | - Kristy K Brock
- Department of Imaging Physics and Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, USA
| | - Marco Fusella
- Department of Radiation Oncology, Abano Terme Hospital, Italy
| | - Nicholas Hardcastle
- Physical Sciences, Peter MacCallum Cancer Centre & Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia
| | - Mohammad Hussein
- Metrology for Medical Physics Centre, National Physical Laboratory, Teddington, United Kingdom
| | - Michael G Jameson
- GenesisCare New South Wales, School of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales, Australia
| | - Isak Wahlstedt
- Department of Health Technology, Technical University of Denmark, Anker Engelunds Vej 1, Bygning 101A, 2800 Kongens Lyngby, Denmark; Department of Oncology, Centre for Cancer and Organ Diseases, Copenhagen University Hospital - Rigshospitalet (RH), Blegdamsvej 9, 2100 Copenhagen, Denmark; Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte (HGH), Borgmester Ib Juuls Vej 7, 2730 Herlev, Denmark
| | - Johnson Yuen
- St George Hospital Cancer Care Centre, Kogarah, NSW 2217, Australia; South Western Clinical School, University of New South Wales, Sydney, Australia; Ingham Institute for Applied Medical Research, Sydney, NSW, Australia
| | - Jamie R McClelland
- Centre for Medical Image Computing and Wellcome/EPSRC Centre for Interventional and Surgical Sciences, Dept of Medical Physics and Biomedical Engineering, UCL, United Kingdom
| | - Eliana Vasquez Osorio
- Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, M20 4BX Manchester, United Kingdom
| |
Collapse
|
19
|
Issa PP, Omar M, Buti Y, Aboueisha M, Munshi R, Hussein M, Haidari M, Blair G, Issa CP, Shama M, Toraih E, Kandil E. Hashimoto's Thyroiditis: A Protective Factor against Recurrence in BRAF-Wild Type Differentiated Thyroid Carcinoma. Cancers (Basel) 2023; 15:cancers15082371. [PMID: 37190300 DOI: 10.3390/cancers15082371] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2023] [Revised: 04/12/2023] [Accepted: 04/15/2023] [Indexed: 05/17/2023] Open
Abstract
A recent work analyzing the concomitant factors BRAF mutation (risk factor) and Hashimoto's thyroiditis (HT) (protective factor) found that the presence of HT reduced lymph node metastasis in BRAF-mutated papillary thyroid carcinoma. Whether this notion is upheld with respect to disease recurrence and differentiated thyroid carcinoma (DTC), however, is unknown. We aimed to investigate the effect of underlying HT in DTC patients and its influence on recurrence with a specific emphasis in BRAF-mutated tumors. A total of 469 patients were included. Patients were stratified according to BRAF and HT status. Multivariate regression analysis was conducted to determine protective and risk factors of disease recurrence in patients with DTC. HT was associated with less-aggressive carcinomas including more frequent microcarcinomas (HT: 45.0% vs. no-HT: 34.0%, p = 0.02), less lymph node involvement (HT: 16.4% vs. no-HT: 26.1%, p = 0.02), and less disease recurrence (HT: 2.9% vs. no-HT: 11.9%, p = 0.002). BRAF mutation was also significantly associated with higher rates of lymph node involvement (BRAF-mutant: 41.9% vs. BRAF-wild type: 14.6%, p < 0.001) and almost two times the rate of recurrence (BRAF-mutant: 14.9% vs. BRAF-wild type: 6.5%, p = 0.004). Underlying HT was the only protective factor determined, reducing the odds of developing recurrence by 70% (HR: 0.30, 95%CI: 0.11-0.88). In the BRAF-wild type cohort, regression analysis continued to determine HT as a protective factor (p = 0.03). However, in the BRAF-mutant cohort, HT was no longer an independent protective factor (p = 0.20) against recurrence. Sub-group regression analysis, including PTC patients, similarly found HT as a protective factor only in BRAF-wild type patients (p = 0.039) and not BRAF-mutant (p = 0.627). The presence of underlying HT is associated with less aggressive tumors and is an independent protective factor against DTC recurrence, reducing the risk by 70%. HT remains a protective factor in BRAF-wild type carcinoma, but not in patients with BRAF-mutant carcinoma. HT may potentially be considered as a parameter which enhances American Thyroid Association patient risk stratification.
Collapse
Affiliation(s)
- Peter P Issa
- Department of Surgery, School of Medicine, Tulane University, New Orleans, LA 70112, USA
- School of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA
| | - Mahmoud Omar
- Department of Surgery, School of Medicine, Tulane University, New Orleans, LA 70112, USA
| | - Yusef Buti
- Department of Surgery, School of Medicine, Tulane University, New Orleans, LA 70112, USA
| | - Mohamed Aboueisha
- Department of Surgery, School of Medicine, Tulane University, New Orleans, LA 70112, USA
| | - Ruhul Munshi
- Department of Surgery, School of Medicine, Tulane University, New Orleans, LA 70112, USA
| | - Mohammad Hussein
- Department of Surgery, School of Medicine, Tulane University, New Orleans, LA 70112, USA
| | - Muhib Haidari
- School of Medicine, Tulane University, New Orleans, LA 70112, USA
| | - Graham Blair
- School of Medicine, Tulane University, New Orleans, LA 70112, USA
| | - Chad P Issa
- School of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA
| | - Mohamed Shama
- Department of Surgery, School of Medicine, Tulane University, New Orleans, LA 70112, USA
| | - Eman Toraih
- Department of Surgery, School of Medicine, Tulane University, New Orleans, LA 70112, USA
- Genetics Unit, Department of Histology and Cell Biology, Faculty of Medicine, Suez Canal University, Ismailia 41522, Egypt
| | - Emad Kandil
- Department of Surgery, School of Medicine, Tulane University, New Orleans, LA 70112, USA
| |
Collapse
|
20
|
Toraih E, Hussein M, Issa PP, Lavorgna T, Kandil E. Letter to the Editor: Chasing π-Fection in Thyroidology. Thyroid 2023; 33:527-528. [PMID: 36416243 DOI: 10.1089/thy.2022.0516] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Affiliation(s)
- Eman Toraih
- Department of Surgery, School of Medicine, Tulane University, New Orleans, Louisiana, USA
- Genetics Unit, Department of Histology and Cell Biology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt
| | - Mohammad Hussein
- Department of Surgery, School of Medicine, Tulane University, New Orleans, Louisiana, USA
| | - Peter P Issa
- School of Medicine, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA
| | - Tessa Lavorgna
- School of Medicine, Tulane University, New Orleans, Louisiana, USA
| | - Emad Kandil
- Department of Surgery, School of Medicine, Tulane University, New Orleans, Louisiana, USA
| |
Collapse
|
21
|
Reinmuth N, Cho B, Luft A, Alexander JA, Geater SL, Laktionov K, Kim SW, Ursol G, Hussein M, Lim F, Yang CT, Araujo L, Saito H, Barrett K, Lowery C, Tattersfield R, Peters S, Garon E, Mok T, Johnson M. 12MO Patterns of response in metastatic (m) NSCLC after 2 and 4 cycles of chemotherapy (CT), alone or with durvalumab (D) ± tremelimumab (T), in the phase III POSEIDON study. J Thorac Oncol 2023. [DOI: 10.1016/s1556-0864(23)00266-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/04/2023]
|
22
|
Kandil E, Metz TA, Issa PP, Aboueisha M, Omar M, Attia AS, Chabot B, Hussein M, Moroz K, Shama M, Toraih E. Diagnostic Performance of Afirma and Interpace Diagnostics Genetic Testing in Indeterminate Thyroid Nodules: A Single Center Study. Cancers (Basel) 2023; 15:cancers15072098. [PMID: 37046759 PMCID: PMC10093254 DOI: 10.3390/cancers15072098] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2023] [Revised: 03/22/2023] [Accepted: 03/27/2023] [Indexed: 04/01/2023] Open
Abstract
Indeterminate thyroid nodules (ITN) represent 20–30% of biopsied nodules, with a 10–60% risk of malignancy. Molecular testing can stratify the risk of malignancy among ITNs, and subsequently reduce the need for unnecessary diagnostic surgery. We aimed to assess the performance of these molecular tests at a single institution. Patients with Bethesda III, IV, and V nodules with Afirma and Interpace Diagnostics genetic testing data from November 2013 to November 2021 were included. Three cohorts were formed, including GSC + XA, ThyGeNEXT + ThyraMIR, and GSC + GEC. Statistical analysis determined the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), diagnostic odds ratio (DOR), and accuracy of each type of testing. The PPV of nodules undergoing genetic testing by ThyGeNEXT + ThyraMIR (45.00%, 95%CI: 28.28–62.93%, p = 0.032) and GSC + XA (57.14%, 95%CI: 29.32–81.08%, p < 0.001) were superior to that of GEC + GSC (30.72%, 95%CI: 26.83–34.90%). The NPV was above 85% in all cohorts, suggesting overall suitable rule-out tests. The Afirma platform (GSC + XA) had the highest NPV at 96.97%. The overall accuracy for nodules undergoing ThyGeNEXT + ThyraMIR was 81.42% (95%CI: 73.01–88.11%, p < 0.001). A total of 230 patients underwent thyroidectomy, including less than 60% of each of the ThyGeNEXT + ThyraMIR and GSC + XA cohorts. Specifically, only 25% of patients in the GSC + XA cohort underwent surgery, considerably decreasing the rate of unnecessary surgical intervention. Sub-group analysis, including only patients with surgical pathology, found that PPV tended to be higher in the GSC + XA cohort, at 66.67% (95%CI: 37.28–87.06%), as compared to the ThyGeNEXT + ThyraMIR cohort, at 52.94% (95%CI: 35.25–69.92%). The Afirma genetic testing platform GSC + XA outperformed the other platforms with regards to both PPV and NPV and decreased the rate of surgery in patients with ITNs by 75%, significantly preventing unnecessary surgical intervention.
Collapse
|
23
|
Cook H, Simard M, Niemann N, Gillies C, Osborne M, Hussein M, Rompokos V, Bouchard H, Royle G, Pettingell J, Palmans H, Lourenço A. Development of optimised tissue-equivalent materials for proton therapy. Phys Med Biol 2023; 68. [PMID: 36696694 DOI: 10.1088/1361-6560/acb637] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2022] [Accepted: 01/25/2023] [Indexed: 01/26/2023]
Abstract
Objective. In proton therapy there is a need for proton optimised tissue-equivalent materials as existing phantom materials can produce large uncertainties in the determination of absorbed dose and range measurements. The aim of this work is to develop and characterise optimised tissue-equivalent materials for proton therapy.Approach. A mathematical model was developed to enable the formulation of epoxy-resin based tissue-equivalent materials that are optimised for all relevant interactions of protons with matter, as well as photon interactions, which play a role in the acquisition of CT numbers. This model developed formulations for vertebra bone- and skeletal muscle-equivalent plastic materials. The tissue equivalence of these new materials and commercial bone- and muscle-equivalent plastic materials were theoretical compared against biological tissue compositions. The new materials were manufactured and characterised by their mass density, relative stopping power (RSP) measurements, and CT scans to evaluate their tissue-equivalence.Main results. Results showed that existing tissue-equivalent materials can produce large uncertainties in proton therapy dosimetry. In particular commercial bone materials showed to have a relative difference up to 8% for range. On the contrary, the best optimised formulations were shown to mimic their target human tissues within 1%-2% for the mass density and RSP. Furthermore, their CT-predicted RSP agreed within 1%-2% of the experimental RSP, confirming their suitability as clinical phantom materials.Significance. We have developed a tool for the formulation of tissue-equivalent materials optimised for proton dosimetry. Our model has enabled the development of proton optimised tissue-equivalent materials which perform better than existing tissue-equivalent materials. These new materials will enable the advancement of clinical proton phantoms for accurate proton dosimetry.
Collapse
Affiliation(s)
- H Cook
- Department of Medical Physics and Biomedical Engineering, University College London, WC1E 6BT, United Kingdom
- Medical Radiation Science, National Physical Laboratory, Teddington, TW11 0LW, United Kingdom
| | - M Simard
- Department of Medical Physics and Biomedical Engineering, University College London, WC1E 6BT, United Kingdom
- Centre de recherche du CHUM, 900 Saint Denis St, Montreal, Quebec H2X 0A9, Canada
- University of Montreal, 2900 Edouard Montpetit Blvd, Montreal, Quebec H3T 1J4, Canada
| | - N Niemann
- Barts Health NHS Trust, Clinical Physics Department, London, E1 2BL, United Kingdom
| | - C Gillies
- Medical Physics Department, Proton Therapy Centre, University College Hospital, WC1E 6AS, United Kingdom
| | - M Osborne
- Medical Physics Department, The Rutherford Cancer Centre Thames Valley, Reading, RG2 9LH, United Kingdom
| | - M Hussein
- Department of Medical Physics and Biomedical Engineering, University College London, WC1E 6BT, United Kingdom
- Medical Radiation Science, National Physical Laboratory, Teddington, TW11 0LW, United Kingdom
| | - V Rompokos
- Medical Physics Department, Proton Therapy Centre, University College Hospital, WC1E 6AS, United Kingdom
| | - H Bouchard
- Centre de recherche du CHUM, 900 Saint Denis St, Montreal, Quebec H2X 0A9, Canada
- University of Montreal, 2900 Edouard Montpetit Blvd, Montreal, Quebec H3T 1J4, Canada
| | - G Royle
- Department of Medical Physics and Biomedical Engineering, University College London, WC1E 6BT, United Kingdom
| | - J Pettingell
- Medical Physics Department, The Rutherford Cancer Centre Thames Valley, Reading, RG2 9LH, United Kingdom
| | - H Palmans
- Medical Radiation Science, National Physical Laboratory, Teddington, TW11 0LW, United Kingdom
- Medical Physics Group, MedAustron Ion Therapy Centre, A-2700 Wiener Neustadt, Austria
| | - A Lourenço
- Department of Medical Physics and Biomedical Engineering, University College London, WC1E 6BT, United Kingdom
- Medical Radiation Science, National Physical Laboratory, Teddington, TW11 0LW, United Kingdom
| |
Collapse
|
24
|
Malas A, El Falou S, El Falou M, Hussein M. Decentralized multi-agent approach based on A* algorithm for on-demand transport problem. WEB 2023. [DOI: 10.3233/web-221659] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/19/2023]
Abstract
The on-demand transport (ODT) systems have developed worldwide as they have significant social, environmental, and economic benefits. Even with those benefits, it’s still important to gain popular acceptance. The acceptance key is the reactivity of the system in providing fast and reliable solutions whilst respecting vehicles’ and clients’ constraints. This paper presents a decentralized multi-agent approach to model and solve the ODT problem in a static road network. The agents interact with each other using the A* algorithm to find an optimal solution for each transport demand. The optimal solution is expressed by the fastest trajectory taken by the cheapest vehicles. We utilize factual data from a Lebanese city to do experiments evaluating the proposed approach.
Collapse
Affiliation(s)
- Anas Malas
- Lebanese University, Tripoli, Lebanon
- Lebanese International University, Tripoli, Lebanon
| | - Salah El Falou
- Lebanese University, Tripoli, Lebanon
- Lebanese International University, Tripoli, Lebanon
| | | | | |
Collapse
|
25
|
Issa PP, Hussein M, Omar M, Munshi R, Attia AS, Buti Y, Aboueisha M, Shama M, Toraih E, Kandil E. Cardiovascular Health by Graves' Disease Management Modality - Surgery Versus Radioactive Iodine Versus Antithyroid Medications: A Network Meta-Analysis. J Surg Res 2023; 283:266-273. [PMID: 36423475 DOI: 10.1016/j.jss.2022.10.043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2022] [Revised: 10/03/2022] [Accepted: 10/18/2022] [Indexed: 11/22/2022]
Abstract
INTRODUCTION Graves' disease is an autoimmune disorder of the thyroid gland associated with the overproduction of thyroid hormones. Excess secretion of thyroid hormones leads to cardiovascular consequences. Treatment options include antithyroid medications (ATM), radioactive iodine (RAI) ablation, and total thyroidectomy. We examined the cardiovascular outcomes following Graves' disease management modality. METHODS A systematic search was performed up to September 22nd, 2021, using PubMed, EMBASE, and Web of Science databases. We conducted a network meta-analysis analyzing cardiovascular outcomes of interest, including congestive heart failure (CHF), arrhythmia, atrial fibrillation (AF), and hypertension. RESULTS Three studies were included in this analysis totaling 6700 patients with Graves' disease, of which 74% were female. The mean age was 44.34 y. When compared to pretreatment, management options lowered the risk of maintaining arrhythmia 81% with surgery (relative risk [RR] = 0.19; 95% confidence interval [CI] = 0.12 to 0.31), 67% with ATM (RR = 0.33; 95% CI = 0.23 to 0.49), and 50% with RAI (RR = 0.50; 95% CI = 0.13 to 1.95). Risk of maintaining CHF was reduced 80% with surgery (RR = 0.20; 95% CI = 0.08 to 0.49), 41% with ATM (RR = 0.59; 95%CI = 0.52 to 0.67), and only 7% with RAI (RR = 0.93; 95%CI = 0.68 to 1.26). Treatment-ranking analysis found all parameters, including CHF, arrhythmia, AF, and hypertension, to be in favor of surgical treatment over medical treatment and RAI ablation. CONCLUSIONS This is the first network meta-analysis analyzing the cardiovascular outcomes in Graves' disease patients by treatment option. Our study demonstrated that surgery is superior to RAI and medical treatment.
Collapse
Affiliation(s)
- Peter P Issa
- School of Medicine, Louisiana State University Health Sciences Center, New Orleans, Louisiana
| | - Mohammad Hussein
- School of Medicine, Department of Surgery, Tulane University, New Orleans, Louisiana
| | - Mahmoud Omar
- School of Medicine, Department of Surgery, Tulane University, New Orleans, Louisiana
| | - Ruhul Munshi
- School of Medicine, Department of Surgery, Tulane University, New Orleans, Louisiana
| | - Abdallah S Attia
- School of Medicine, Department of Surgery, Tulane University, New Orleans, Louisiana
| | - Yusef Buti
- School of Medicine, Department of Surgery, Tulane University, New Orleans, Louisiana
| | - Mohamed Aboueisha
- School of Medicine, Department of Surgery, Tulane University, New Orleans, Louisiana; Faculty of Medicine, Department of Otolaryngology-Head and Neck Surgery, Suez Canal University, Ismailia, Egypt
| | - Mohamed Shama
- School of Medicine, Department of Surgery, Tulane University, New Orleans, Louisiana
| | - Eman Toraih
- School of Medicine, Department of Surgery, Tulane University, New Orleans, Louisiana; Genetics Unit, Faculty of Medicine, Department of Histology and Cell Biology, Suez Canal University, Ismailia, Egypt
| | - Emad Kandil
- School of Medicine, Department of Surgery, Tulane University, New Orleans, Louisiana.
| |
Collapse
|
26
|
Hussein M, Mueller L, Issa PP, Haidari M, Trinh L, Toraih E, Kandil E. Sexual disparity and the risk of second primary thyroid cancer: a paradox. Gland Surg 2023; 12:432-441. [DOI: 10.21037/gs-22-411] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2022] [Accepted: 02/19/2023] [Indexed: 03/30/2023]
|
27
|
Issa PP, Albuck AL, Hossam E, Hussein M, Aboueisha M, Attia AS, Omar M, Abdelrahman S, Naser G, Clark RDE, Toraih E, Kandil E. The Diagnostic Performance of Ultrasonography in the Evaluation of Extrathyroidal Extension in Papillary Thyroid Carcinoma: A Systematic Review and Meta-Analysis. Int J Mol Sci 2022; 24:ijms24010371. [PMID: 36613811 PMCID: PMC9820513 DOI: 10.3390/ijms24010371] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2022] [Revised: 12/04/2022] [Accepted: 12/20/2022] [Indexed: 12/28/2022] Open
Abstract
Extrathyroidal extension (ETE) in patients with papillary thyroid carcinoma (PTC) is an indication of disease progression and can influence treatment aggressiveness. This meta-analysis assesses the diagnostic accuracy of ultrasonography (US) in detecting ETE. A systematic review and meta-analysis were performed by searching PubMed, Embase, and Cochrane for studies published up to April 2022. The pooled sensitivity, specificity, and diagnostic odds ratio (DOR) were calculated. The areas under the curve (AUC) for summary receiver operating curves were compared. A total of 11 studies analyzed ETE in 3795 patients with PTC. The sensitivity of ETE detection was 76% (95%CI = 74-78%). The specificity of ETE detection was 51% (95%CI = 49-54%). The DOR of detecting ETE by US was 5.32 (95%CI = 2.54-11.14). The AUC of ETE detection was determined to be 0.6874 ± 0.0841. We report an up-to-date analysis elucidating the diagnostic accuracy of ETE detection by US. Our work suggests the diagnostic accuracy of US in detecting ETE is adequate. Considering the importance of ETE detection on preoperative assessment, ancillary studies such as adjunct imaging studies and genetic testing should be considered.
Collapse
Affiliation(s)
- Peter P. Issa
- School of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA
| | - Aaron L. Albuck
- School of Medicine, Tulane University, New Orleans, LA 70112, USA
| | - Eslam Hossam
- Surgical Oncology Department, National Cancer Institute, Cairo University, Cairo 11796, Egypt
| | - Mohammad Hussein
- School of Medicine, Tulane University, New Orleans, LA 70112, USA
| | | | | | - Mahmoud Omar
- School of Medicine, Tulane University, New Orleans, LA 70112, USA
| | - Seif Abdelrahman
- School of Medicine, Tulane University, New Orleans, LA 70112, USA
| | - Gehad Naser
- School of Medicine, Tulane University, New Orleans, LA 70112, USA
| | | | - Eman Toraih
- School of Medicine, Tulane University, New Orleans, LA 70112, USA
- Genetics Unit, Department of Histology and Cell Biology, Faculty of Medicine, Suez Canal University, Ismailia 41522, Egypt
- Correspondence: ; Tel.: +1-504-988-7407; Fax: +1-504-988-4762
| | - Emad Kandil
- School of Medicine, Tulane University, New Orleans, LA 70112, USA
| |
Collapse
|
28
|
Zhang J, Hussein M, Kao SH, Clay T, Singhal N, Kim H, Cho E, Shim B, Lee Y, Lee GW, Zhao J, Yu Y, Sun M, Lin CB, Yang TY, Chang GC, Zheng H, Tan W, Spigel D. 148P AdvanTIG-105: Phase Ib dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC). Immuno-Oncology and Technology 2022. [DOI: 10.1016/j.iotech.2022.100260] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
29
|
Hernandez V, Angerud A, Bogaert E, Hussein M, Lemire M, García-Miguel J, Saez J. Challenges in modeling the Agility multileaf collimator in treatment planning systems and current needs for improvement. Med Phys 2022; 49:7404-7416. [PMID: 36217283 PMCID: PMC10092639 DOI: 10.1002/mp.16016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2022] [Revised: 08/22/2022] [Accepted: 09/12/2022] [Indexed: 12/27/2022] Open
Abstract
BACKGROUND The Agility multileaf collimator (MLC) mounted in Elekta linear accelerators features some unique design characteristics, such as large leaf thickness, eccentric curvature at the leaf tip, and defocused leaf sides ('tilting'). These characteristics offer several advantages but modeling them in treatment planning systems (TPSs) is challenging. PURPOSE The goals of this study were to investigate the challenges faced when modeling the Agility in two commercial TPSs (Monaco and RayStation) and to explore how the implemented MLC models could be improved in the future. METHODS Four linear accelerators equipped with the Agility, located at different centers, were used for the study. Three centers use the RayStation TPS and the other one uses Monaco. For comparison purposes, data from four Varian linear accelerators with the Millennium 120 MLC were also included. Average doses measured with asynchronous sweeping gap tests were used to characterize and compare the characteristics of the Millennium and the Agility MLCs and to assess the MLC model in the TPSs. The FOURL test included in the ExpressQA package, provided by Elekta, was also used to evaluate the tongue-and-groove with radiochromic films. Finally, raytracing was used to investigate the impact of the MLC geometry and to understand the results obtained for each MLC. RESULTS The geometry of the Agility produces dosimetric effects associated with the rounded leaf end up to a distance 20 mm away from the leaf tip end measured at the isocenter plane. This affects the tongue-and-groove shadowing, which progressively increases along the distance to the tip end. The RayStation and Monaco TPSs did not account for this effect, which made trade-offs in the MLC parameters necessary and greatly varied the final MLC parameters used by different centers. Raytracing showed that these challenging leaf tip effects were directly related to the MLC geometry and that the characteristics mainly responsible for the large leaf tip effects of the Agility were its tilting design and its small source-to-collimator distance. CONCLUSIONS The MLC models implemented in RayStation and Monaco could not accurately reproduce the leaf tip effects for the Agility. Therefore, trade-offs are needed and the optimal MLC parameters are dependent on the specific characteristics of treatment plans. Refining the MLC models for the Agility to better approximate the measured leaf tip and tongue-and-groove effects would extend the validity of the MLC model, reduce the variability in the MLC parameters used by the community, and facilitate the standardization of the MLC configuration process.
Collapse
Affiliation(s)
- V Hernandez
- Department of Medical Physics, Hospital Sant Joan de Reus, IISPV, Tarragona, Spain.,Universitat Rovira i Virgili (URV), Tarragona, Spain
| | - A Angerud
- RaySearch Laboratories AB, Stockholm, Sweden
| | - E Bogaert
- Department of Radiation Oncology, Ghent University Hospital and Ghent University, Ghent, Belgium
| | - M Hussein
- Metrology for Medical Physics Centre, National Physical Laboratory, Teddington, UK
| | - M Lemire
- Department of Medical Physics, CIUSSS de l'Est-de-l'Île-de-Montréal, Montreal, QC, Canada
| | - J García-Miguel
- Department of Radiation Oncology, Consorci Sanitari de Terrassa, Barcelona, Spain
| | - J Saez
- Department of Radiation Oncology, Hospital Clínic de Barcelona, Barcelona, Spain
| |
Collapse
|
30
|
Cho B, Luft A, Alatorre Alexander J, Lucien Geater S, Laktionov K, Sang-We K, Ursol G, Hussein M, Lim Farah L, Yang C, Araujo L, Saito H, Reinmuth N, Lai Z, Mann H, Shi X, Peters S, Garon E, Mok T, Johnson M. 326P Durvalumab (D) ± tremelimumab (T) + chemotherapy (CT) in 1L metastatic (m) NSCLC: Overall survival (OS) update from POSEIDON after median follow-up (mFU) of approximately 4 years (y). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.365] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/07/2022] Open
|
31
|
Issa PP, Mueller L, Hussein M, Albuck A, Shama M, Toraih E, Kandil E. Radiologist versus Non-Radiologist Detection of Lymph Node Metastasis in Papillary Thyroid Carcinoma by Ultrasound: A Meta-Analysis. Biomedicines 2022; 10:biomedicines10102575. [PMID: 36289838 PMCID: PMC9599420 DOI: 10.3390/biomedicines10102575] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2022] [Revised: 10/08/2022] [Accepted: 10/09/2022] [Indexed: 11/16/2022] Open
Abstract
Papillary thyroid carcinoma (PTC) is the most common thyroid cancer worldwide and is known to spread to adjacent neck lymphatics. Lymph node metastasis (LNM) is a known predictor of disease recurrence and is an indicator for aggressive resection. Our study aims to determine if ultrasound sonographers’ degree of training influences overall LNM detection. PubMed, Embase, and Scopus articles were searched and screened for relevant articles. Two investigators independently screened and extracted the data. Diagnostic test parameters were determined for all studies, studies reported by radiologists, and studies reported by non-radiologists. The total sample size amounted to 5768 patients and 10,030 lymph nodes. Radiologists performed ultrasounds in 18 studies, while non-radiologists performed ultrasounds in seven studies, corresponding to 4442 and 1326 patients, respectively. The overall sensitivity of LNM detection by US was 59% (95%CI = 58–60%), and the overall specificity was 85% (95%CI = 84–86%). The sensitivity and specificity of US performed by radiologists were 58% and 86%, respectively. The sensitivity and specificity of US performed by non-radiologists were 62% and 78%, respectively. Summary receiver operating curve (sROC) found radiologists and non-radiologists to detect LNM on US with similar accuracy (p = 0.517). Our work suggests that both radiologists and non-radiologists alike detect overall LNM with high accuracy on US.
Collapse
Affiliation(s)
- Peter P. Issa
- School of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA
| | - Lauren Mueller
- School of Medicine, Tulane University, New Orleans, LA 70112, USA
| | - Mohammad Hussein
- Department of Surgery, School of Medicine, Tulane University, New Orleans, LA 70112, USA
| | - Aaron Albuck
- School of Medicine, Tulane University, New Orleans, LA 70112, USA
| | - Mohamed Shama
- Department of Surgery, School of Medicine, Tulane University, New Orleans, LA 70112, USA
| | - Eman Toraih
- Department of Surgery, School of Medicine, Tulane University, New Orleans, LA 70112, USA
- Genetics Unit, Department of Histology and Cell Biology, Faculty of Medicine, Suez Canal University, Ismailia 41522, Egypt
| | - Emad Kandil
- Department of Surgery, School of Medicine, Tulane University, New Orleans, LA 70112, USA
- Correspondence: ; Tel.: +1-504-988-7407; Fax: +1-504-988-4762
| |
Collapse
|
32
|
Lavorgna TR, Hussein M, Issa PP, Toraih E, Kandil E. Ultraviolet Light Exposure Decreases Thyroid Cancer Risk: A National Perspective. Biomedicines 2022; 10:biomedicines10102452. [PMID: 36289713 PMCID: PMC9598664 DOI: 10.3390/biomedicines10102452] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2022] [Revised: 09/23/2022] [Accepted: 09/25/2022] [Indexed: 11/16/2022] Open
Abstract
Ultraviolet (UV) light has been reported to have both pro-oncogenic and anti-oncogenic effects. Since patient pigmentation can influence the role of UV light exposure, we thought to investigate the recent trends in thyroid cancer incidence and survival with an emphasis on patient race and UV exposure. Patients diagnosed with thyroid cancer from the Surveillance, Epidemiology, and End Results (SEER) database were identified. A total of 284,178 patients were enrolled. Data were stratified according to population sex, race, and state. UV exposure data in Watt-Hours Per Square Meter for the state were obtained from the National Cancer Institute Cancer Atlas. Thyroid cancer incidence rate varied by race, ranging from 14.9 cases per 100,000 in Asian or Pacific Islanders and 14.7 per 100,000 in Caucasians, to 8.7 per 100,000 in African American and 8.0 per 100,000 in Native Americans. UV exposure was negatively correlated with thyroid cancer incidence when analyzed across all populations (r = −0.299, p = 0.035). UV exposure was most steeply negatively correlated with thyroid cancer rates in Black populations (r = −0.56, p < 0.001). Despite this, Black men had the worst 5-year survival rate when compared to other ethnic populations. Overall, UV exposure does not increase the risk of thyroid cancer and may serve as a protective factor in the development of thyroid cancer.
Collapse
Affiliation(s)
| | - Mohammad Hussein
- Department of Surgery, School of Medicine, Tulane University, New Orleans, LA 70112, USA
| | - Peter P. Issa
- School of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA
| | - Eman Toraih
- Department of Surgery, School of Medicine, Tulane University, New Orleans, LA 70112, USA
- Genetics Unit, Department of Histology and Cell Biology, Faculty of Medicine, Suez Canal University, Ismailia 41522, Egypt
- Correspondence: ; Tel.: +1-504-988-2301; Fax: +1-504-988-4762
| | - Emad Kandil
- Department of Surgery, School of Medicine, Tulane University, New Orleans, LA 70112, USA
| |
Collapse
|
33
|
Issa PP, Omar M, Issa CP, Buti Y, Hussein M, Aboueisha M, Abdelhady A, Shama M, Lee GS, Toraih E, Kandil E. Radiofrequency Ablation of Indeterminate Thyroid Nodules: The First North American Comparative Analysis. Int J Mol Sci 2022; 23:ijms231911493. [PMID: 36232815 PMCID: PMC9569520 DOI: 10.3390/ijms231911493] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2022] [Revised: 09/13/2022] [Accepted: 09/27/2022] [Indexed: 11/22/2022] Open
Abstract
Thyroid nodules can be classified as benign, malignant, or indeterminate, the latter of which make up 10-30% of nodules. Radiofrequency ablation (RFA) has become an attractive and promising therapy for the treatment of benign thyroid nodules. However, few studies have investigated the safety and efficacy of RFA for the management of indeterminate thyroid nodules. In this study, 178 patients with thyroid nodules diagnosed as benign (Bethesda II) or indeterminate (Bethesda III/IV) by preoperative cytopathological analysis were included. Patients in the benign and indeterminate cohorts had similar thyroid nodule volume reduction rates at 65.60% and 64.20%, respectively (p = 0.68). The two groups had similar nodular regrowth rates, at 11.2% for benign nodules and 9.40% for indeterminate nodules (p = 0.72). A total of three cases of transient dysphonia were reported. RFA of indeterminate thyroid nodules was comparable to that of benign thyroid nodules in all parameters of interest, including volume reduction rate. To our best knowledge, our work is the first North American analysis comparing benign and indeterminate thyroid nodules and suggests RFA to be a promising modality for the management of indeterminate thyroid nodules.
Collapse
Affiliation(s)
- Peter P. Issa
- School of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA
| | - Mahmoud Omar
- Department of Surgery, School of Medicine, Tulane University, New Orleans, LA 70112, USA
| | - Chad P. Issa
- School of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA
| | - Yusef Buti
- Department of Surgery, School of Medicine, Tulane University, New Orleans, LA 70112, USA
- Department of Surgery, United Health Services Southern California Medical Education Consortium, Temecula Valley Hospital, Temecula, CA 92592, USA
| | - Mohammad Hussein
- Department of Surgery, School of Medicine, Tulane University, New Orleans, LA 70112, USA
| | - Mohamed Aboueisha
- Department of Surgery, School of Medicine, Tulane University, New Orleans, LA 70112, USA
| | - Ali Abdelhady
- Department of Surgery, School of Medicine, Tulane University, New Orleans, LA 70112, USA
| | - Mohamed Shama
- Department of Surgery, School of Medicine, Tulane University, New Orleans, LA 70112, USA
| | - Grace S. Lee
- Department of Surgery, School of Medicine, Yale University, New Haven, CT 06520, USA
| | - Eman Toraih
- Department of Surgery, School of Medicine, Tulane University, New Orleans, LA 70112, USA
- Genetics Unit, Department of Histology and Cell Biology, Faculty of Medicine, Suez Canal University, Ismailia 41522, Egypt
| | - Emad Kandil
- Department of Surgery, School of Medicine, Tulane University, New Orleans, LA 70112, USA
- Correspondence: ; Tel.: +1-504-988-7407; Fax: +1-504-988-4762
| |
Collapse
|
34
|
Ahn MJ, Spigel D, Bondarenko I, Kalinka E, Cho B, Sugawara S, Galffy G, Shim B, Kislov N, Nagarkar R, Demedts I, Gans S, Oliva D, Stewart R, Lai Z, Grainger E, Shi X, Hussein M. P1.15-11 Durvalumab + Olaparib vs Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: Outcomes from the Phase 2 ORION Study. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.207] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
35
|
Garon E, Cho B, Luft A, Alatorre-Alexander J, Geater S, Kim SW, Ursol G, Hussein M, Lim F, Yang CT, Araujo L, Saito H, Reinmuth N, Kohlmann M, Shi X, Mann H, Peters S, Mok T, Johnson M. EP08.01-027 Durvalumab (D) ± Tremelimumab (T) + Chemotherapy (CT) in 1L Metastatic NSCLC: Outcomes by Tumour PD-L1 Expression in POSEIDON. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.599] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
36
|
Peters S, Cho B, Luft A, Alatorre-Alexander J, Geater S, Kim SW, Ursol G, Hussein M, Lim F, Yang CT, Araujo L, Saito H, Reinmuth N, Stewart R, Lai Z, Doake R, Krug L, Garon E, Mok T, Johnson M. OA15.04 Association Between KRAS/STK11/KEAP1 Mutations and Outcomes in POSEIDON: Durvalumab ± Tremelimumab + Chemotherapy in mNSCLC. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
37
|
Issa PP, Omar M, Buti Y, Issa CP, Chabot B, Carnabatu CJ, Munshi R, Hussein M, Aboueisha M, Shama M, Corsetti RL, Toraih E, Kandil E. Hashimoto’s Thyroiditis Minimizes Lymph Node Metastasis in BRAF Mutant Papillary Thyroid Carcinomas. Biomedicines 2022; 10:biomedicines10082051. [PMID: 36009596 PMCID: PMC9405831 DOI: 10.3390/biomedicines10082051] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2022] [Revised: 08/16/2022] [Accepted: 08/18/2022] [Indexed: 12/03/2022] Open
Abstract
Hashimoto’s thyroiditis (HT) (autoimmune thyroiditis) is a clinicopathological entity associated with chronic lymphocytic infiltration resulting in hypothyroidism. HT is a double-edged sword that increases the risk of papillary thyroid cancer (PTC), yet it serves as a protective factor for PTC progression. BRAF mutation in PTCs is associated with rapid cell growth, aggressive tumor characteristics, and higher mortality rates. Here, we aimed to analyze the influence of HT in patients with PTCs and its effect on lymph node metastasis (LNM) in BRAF mutant tumors. Adults diagnosed with PTC between 2008 and January 2021 were retrospectively included. A total of 427 patients, 128 of whom had underlying HT, were included. The HT group had significantly higher rates of microcarcinoma (49.2% vs. 37.5%, p = 0.025) and less lateral LNM (8.6% vs. 17.1%, p = 0.024). Interestingly, BRAF-mutated PTCs were found to have significantly less overall LNM (20.9% vs. 51%, p = 0.001), central LNM (25.6% vs. 45.1%, p = 0.040) and lateral LNM (9.3% vs. 29.4%, p = 0.010) in patients with HT when compared to those without underlying HT. HT was found to be an independent protective predictor of overall and lateral LNM. Altogether, HT was able to neutralize the effect of BRAF mutation and was determined to be an independent protective factor against LNM. Specifically, our work may influence treatment-aggressiveness decision making for endocrinologists, oncologists and surgeons alike.
Collapse
Affiliation(s)
- Peter P. Issa
- School of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA
| | - Mahmoud Omar
- Department of Surgery, School of Medicine, Tulane University, New Orleans, LA 70112, USA
| | - Yusef Buti
- Department of Surgery, School of Medicine, Tulane University, New Orleans, LA 70112, USA
| | - Chad P. Issa
- School of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA
| | - Bert Chabot
- Department of Surgery, School of Medicine, Tulane University, New Orleans, LA 70112, USA
| | | | - Ruhul Munshi
- Department of Surgery, School of Medicine, Tulane University, New Orleans, LA 70112, USA
| | - Mohammad Hussein
- Department of Surgery, School of Medicine, Tulane University, New Orleans, LA 70112, USA
| | - Mohamed Aboueisha
- Department of Surgery, School of Medicine, Tulane University, New Orleans, LA 70112, USA
| | - Mohamed Shama
- Department of Surgery, School of Medicine, Tulane University, New Orleans, LA 70112, USA
| | - Ralph L. Corsetti
- Department of Surgery, School of Medicine, Tulane University, New Orleans, LA 70112, USA
| | - Eman Toraih
- Department of Surgery, School of Medicine, Tulane University, New Orleans, LA 70112, USA
- Genetics Unit, Department of Histology and Cell Biology, Faculty of Medicine, Suez Canal University, Ismailia 41522, Egypt
| | - Emad Kandil
- Department of Surgery, School of Medicine, Tulane University, New Orleans, LA 70112, USA
- Correspondence: ; Tel.: + 504-988-7407; Fax: + 504-988-4762
| |
Collapse
|
38
|
Dockry EF, Hussein M, Murphy CA, El-Khuffash A. Factors Affecting Exclusive Breastfeeding at a Tertiary Maternity Hospital. Ir Med J 2022; 115:640. [PMID: 36301235] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/16/2023]
Affiliation(s)
- E F Dockry
- Department of Neonatology, Rotunda Hospital, Dublin 1
| | - M Hussein
- Department of Neonatology, Rotunda Hospital, Dublin 1
| | - C A Murphy
- Department of Neonatology, Rotunda Hospital, Dublin 1
- Department of Paediatrics, Royal College of Surgeons in Ireland, Dublin 2
| | - A El-Khuffash
- Department of Neonatology, Rotunda Hospital, Dublin 1
- Department of Paediatrics, Royal College of Surgeons in Ireland, Dublin 2
| |
Collapse
|
39
|
Hussein M, Mueller L, Issa PP, Haidari M, Trinh L, Toraih E, Kandil E. Latency Trend Analysis as a Guide to Screening Malignancy Survivors for Second Primary Thyroid Cancer. Biomedicines 2022; 10:biomedicines10081984. [PMID: 36009531 PMCID: PMC9406053 DOI: 10.3390/biomedicines10081984] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2022] [Revised: 08/10/2022] [Accepted: 08/11/2022] [Indexed: 11/29/2022] Open
Abstract
Primary cancer survivors have a higher risk of developing second primary thyroid cancer (SPTC). Patients with SPTC who survived primary malignancies, diagnosed from 1975 to 2016, were identified from the Surveillance, Epidemiology, and End Results (SEER) database (SEER 18 Registry). A total of 33,551 cancer cases were enrolled in the final analysis. Individuals with a primary malignancy were at a significant 90% increased risk of developing SPTC (SIR = 1.90, 95%CI = 1.86−1.93, p < 0.05) compared to the general population. More than half (54.7%) of SPTC diagnoses were made in the first three years after primary cancer diagnosis, and the most aggressive presentations of SPTC occurred within the first year following malignancy. A latency trend analysis identified persistent high risk for development of SPTC after diagnosis of lymphoma, leukemia, soft tissue tumors, kidney, breast, and uterine cancer; elevated 10-year risk for most cancers such as salivary gland, melanoma, stomach, lung, colon, ovarian, pancreas, prostate, and bladder; and high 5-year risk after cancers such as larynx, oral, orbit, bone, small intestine, and liver. Our latency period model identifying risk according to each type of primary cancer may aid clinicians in identifying at-risk patients to be screened for thyroid cancer and guide them in developing a surveillance plan according to the latency period attributed to a patient’s primary cancer.
Collapse
Affiliation(s)
- Mohammad Hussein
- Department of Surgery, School of Medicine, Tulane University, New Orleans, LA 70112, USA
| | - Lauren Mueller
- School of Medicine, Tulane University, New Orleans, LA 70112, USA
| | - Peter P. Issa
- School of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA
| | - Muhib Haidari
- School of Medicine, Tulane University, New Orleans, LA 70112, USA
| | - Lily Trinh
- School of Medicine, Tulane University, New Orleans, LA 70112, USA
- Division of Thyroid and Parathyroid Endocrine Surgery, Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA 02114, USA
| | - Eman Toraih
- Department of Surgery, School of Medicine, Tulane University, New Orleans, LA 70112, USA
- Genetics Unit, Department of Histology and Cell Biology, Faculty of Medicine, Suez Canal University, Ismailia 41522, Egypt
- Correspondence: ; Tel.: +1-504-988-2301; Fax: +1-504-988-4762
| | - Emad Kandil
- Department of Surgery, School of Medicine, Tulane University, New Orleans, LA 70112, USA
| |
Collapse
|
40
|
Malas A, El Falou S, El Falou M, Hussein M. A multi-agent approach for on-demand transportation problem in cities. WEB 2022. [DOI: 10.3233/web-220004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
On-demand transportation (ODT) systems have proliferated in diverse cities worldwide due to their social, economic and environmental advantages. Despite those advantages, it is vital to get public approval. The approval key is the system’s reactivity in supplying speedy and reliable solutions that consider clients’ and vehicles’ constraints. Those solutions have to reflect actual life conditions to optimize the quality of service. The most regarded challenge in studying the ODT problem in cities is the stochastic time-dependent travel speed that varies due to traffic fluctuations. To deal with an actual ODT problem, a system has to represent the traffic on its scale. Hence, estimating the travel speed at a specific time and affording a solution based on reliable traffic data. Accordingly, the passengers are served better. This work contributes to the study by solving the ODT problem in cities with a massive multi-agent system that considers historical traffic data and unpredictable events disrupting the typical traffic. We evaluate the proposed approach by experiments with instances based on actual data for a city in the north of Lebanon. The results reveal that the quality of service increases when the stochastic time-dependent travel speed is considered. 50% to 100% of affected clients by an unpredictable event are satisfied when this event is considered by the system.
Collapse
|
41
|
Nwose S, AkiiBua A, Hussein M. P19 Audit of completion and documentation of neurovascular assessment prior to, and after Bier's block for distal radius fracture. Br J Surg 2022. [DOI: 10.1093/bjs/znac231.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Abstract
Introduction
The BOAST guideline's standard of practise for the management of distal Radius Fractures states that assessment of circulation and sensation should be documented prior to and after MUA for distal radius fractures. We measured the compliance of the completion and documentation of the neurovascular assessment prior to and after Bier's Block for MUA of distal radius fractures.
Methods
We assessed electronic medical records of these patients during the period November/December 2020. Focusing on the completion of the neurovascular assessment and documentation prior to Bier's Block and compared the results to our first cycle audit done in July/August 2020 following our intervention.
Results
58 patients were analysed for this study compared to 50 in the initial study. 88% had neurovascular assessment done and documented in the Emergency Department compared to 98% in the initial study. However, 60.3% had documentation of neurovascular assessment prior to Bier's block compared to 34% previously. 39.7% had vascular assessment after Bier's block and 64% had neurovascular assessment done in fracture clinic in this second cycle compared to 22% and 76% for vascular assessment and Neurovascular assessment in the facture clinic respectively after the MUA.
Conclusion
This re- audit shows an improvement in the assessment and documentation of neurovascular Status prior to and following MUA of distal radius fracture. There is however a need for improvement. Suggested methods include teaching of upper limb neurological assessment to orthopaedic juniors, Aide memoire such as a small sticker to attach to the notes/ Stamp in the fracture clinic notes.
Take-home message
Assessing and documenting neurovascular status before and after an MUA is very important.
Collapse
Affiliation(s)
- S Nwose
- Queen’s Medical Centre , Nottingham
| | | | | |
Collapse
|
42
|
Bayraktar M, Hussein M, Hassan H. Determination genetic variation and phylogenetic analysis in Echinococcus granulosus isolated from Iraqi sheep. J HELL VET MED SOC 2022. [DOI: 10.12681/jhvms.28066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
Echinococcus granulosus causes Cystic Echinococcosis disease in intermediate hosts, such as sheep, cattle, goats, camels, and horses. Cystic Echinococcosis is an essential parasitic zoonosis that affects humans and animals and is a significant public health and economic problem worldwide. This study aimed to determine the molecular characterization and phylogenetic analysis of Echinococcus granulosus in sheep's livers and lungs. The genetic variation was performed by directly sequencing the mitochondrial DNA (mtDNA) genes coding of the NADH dehydrogenase subunit 1 (ND1). The evidence from molecular studies and DNA sequencing revealed that the Isolates of Echinococcus granulosus in Kirkuk city related to the sheep strain G1 genotype. The alignment analysis showed a concordance between isolates with each other by 99%. When comparing the results with Genbank, it indicated the occurrence of genetic variations between nucleotides represented by eleven codons, seven of which represent transversion mutations, and four are transition mutations.
Collapse
|
43
|
Kaplan LP, Placidi L, Bäck A, Canters R, Hussein M, Vaniqui A, Fusella M, Piotrowski T, Hernandez V, Jornet N, Hansen CR, Widesott L. Plan quality assessment in clinical practice: Results of the 2020 ESTRO survey on plan complexity and robustness. Radiother Oncol 2022; 173:254-261. [PMID: 35714808 DOI: 10.1016/j.radonc.2022.06.005] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2022] [Revised: 05/24/2022] [Accepted: 06/07/2022] [Indexed: 10/18/2022]
Abstract
PURPOSE Plan complexity and robustness are two essential aspects of treatment plan quality but there is a great variability in their management in clinical practice. This study reports the results of the 2020 ESTRO survey on plan complexity and robustness to identify needs and guide future discussions and consensus. METHODS A survey was distributed online to ESTRO members. Plan complexity was defined as the modulation of machine parameters and increased uncertainty in dose calculation and delivery. Robustness was defined as a dose distribution's sensitivity towards errors stemming from treatment uncertainties, patient setup, or anatomical changes. RESULTS A total of 126 radiotherapy centres from 33 countries participated, 95 of them (75%) from Europe and Central Asia. The majority controlled and evaluated plan complexity using monitor units (56 centres) and aperture shapes (38 centres). To control robustness, 98 (97% of question responses) photon and 5 (50%) proton centres used PTV margins for plan optimization while 75 (94%) and 5 (50%), respectively, used margins for plan evaluation. Seventeen (21%) photon and 8 (80%) proton centres used robust optimisation, while 10 (13%) and 8 (80%), respectively, used robust evaluation. Primary uncertainties considered were patient setup (photons and protons) and range calculation uncertainties (protons). Participants expressed the need for improved commercial tools to control and evaluate plan complexity and robustness. CONCLUSION Clinical implementation of methods to control and evaluate plan complexity and robustness is very heterogeneous. Better tools are needed to manage complexity and robustness in treatment planning systems. International guidelines may promote harmonization.
Collapse
Affiliation(s)
- Laura Patricia Kaplan
- Department of Oncology, Aarhus University Hospital, Denmark; Department of Clinical Medicine, Aarhus University, Denmark.
| | - Lorenzo Placidi
- Fondazione Policlinico Universitario ''A. Gemelli'' IRCCS, Roma, Italy.
| | - Anna Bäck
- Department of Therapeutic Radiation Physics, Sahlgrenska University Hospital, Gothenburg, Sweden; Department of Medical Radiation Sciences, Sahlgrenska Academy, University of Gothenburg, Sweden
| | - Richard Canters
- Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht University Medical Centre+, the Netherlands
| | - Mohammad Hussein
- Metrology for Med Phys Centre, National Physical Laboratory, Teddington, United Kingdom
| | - Ana Vaniqui
- Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht University Medical Centre+, the Netherlands
| | - Marco Fusella
- Department of Med Phys, Veneto Institute of Oncology - IOV IRCCS, Padua, Italy
| | - Tomasz Piotrowski
- Department of Electroradiology, Poznan University of Medical Sciences and Department of Med Phys, Greater Poland Cancer Centre, Poznan, Poland
| | - Victor Hernandez
- Department of Med Phys, Hospital Sant Joan de Reus, IISPV, Spain
| | - Nuria Jornet
- Servei de Radiofísica i Radioprotecció, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - Christian Rønn Hansen
- Laboratory of Radiation Physics, Department of Oncology, Odense University Hospital, Denmark; Danish Centre for Particle Therapy, Aarhus University Hospital, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark
| | | |
Collapse
|
44
|
Shihabi AN, Hussein M, Toraih EA, Attia AS, Youssef MR, Elnahla A, Omar M, Shama M, Corsetti R, Kandil E. Accuracy of the 'CUT' Score for Assessing Malignancy in Bethesda 3 and 4 Thyroid Nodules in North American population: a retrospective study. Cancer Invest 2022; 40:693-699. [PMID: 35549502 DOI: 10.1080/07357907.2022.2077956] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
BACKGROUND The CUT score is a thyroid nodule malignancy risk assessment scoring system intended to guide surgeons in treating Bethesda 3 and 4 thyroid nodules. It is based on clinical (C) and ultrasonographic (U) features and a five-tiered (T) representing cytology. PURPOSE Our study aimed to assess the utility of the CUT score in predicting thyroid malignancy in the North American population. The main reason for creating this score is to reduce unnecessary surgeries on these challenging thyroid nodules. MATERIALS AND METHODS A retrospective record review study applied the CUT score to 219 Bethesda 3 and 4 thyroid nodules. A total of 203 Bethesda 3 and 16 Bethesda 4 nodules from patients treated between January 2015 and December 2019 at a single institution were assessed. A receiver operating characteristic (ROC) curve analysis was performed to evaluate the CUT diagnostic test. Binary logistic regression analysis was performed. Iteration of analysis was performed after stratification according to body mass index to assess CUT score accuracy in obese and non-obese patients. RESULTS Of 219 nodules analyzed, 148 were characterized as benign and 71 as malignant. Prevalence rates of malignancy were 29.6% (n = 60) and 68.8% (n = 11) in Bethesda 3 and 4 nodules, respectively. The mean CU (clinical, ultrasonography) score was 5.35 ± 1.38 in benign nodules versus 4.96 ± 1.5 in malignant nodules (p = 0.08). The area under the curve (AUC =0.433) for the association of CUT scores with nodule malignancy was not significant (p = 0.13). The CUT score was insignificant as a diagnostic test for nodule malignancy in obese (AUC =0.45; p = 0.72) and non-obese patients (AUC =0.39; p = 0.08). CONCLUSION The CUT score did not correlate with preoperative malignancy risk estimates in Bethesda 3 thyroid nodules and, therefore, may have limited utility as a predictor of malignancy in these thyroid nodules.
Collapse
Affiliation(s)
- Areej N Shihabi
- Department of Surgery, School of Medicine, Tulane University, New Orleans, Louisiana, 70112, USA
| | - Mohammad Hussein
- Department of Surgery, School of Medicine, Tulane University, New Orleans, Louisiana, 70112, USA
| | - Eman A Toraih
- Department of Surgery, School of Medicine, Tulane University, New Orleans, Louisiana, 70112, USA.,Genetics Unit, Department of Histology and Cell Biology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt
| | - Abdallah S Attia
- Department of Surgery, School of Medicine, Tulane University, New Orleans, Louisiana, 70112, USA
| | - Mohanad R Youssef
- Department of Surgery, School of Medicine, Tulane University, New Orleans, Louisiana, 70112, USA
| | - Ahmed Elnahla
- Department of Surgery, School of Medicine, Tulane University, New Orleans, Louisiana, 70112, USA
| | - Mahmoud Omar
- Department of Surgery, School of Medicine, Tulane University, New Orleans, Louisiana, 70112, USA
| | - Mohamed Shama
- Department of Surgery, School of Medicine, Tulane University, New Orleans, Louisiana, 70112, USA
| | - Ralph Corsetti
- Department of Surgery, School of Medicine, Tulane University, New Orleans, Louisiana, 70112, USA
| | - Emad Kandil
- Department of Surgery, School of Medicine, Tulane University, New Orleans, Louisiana, 70112, USA
| |
Collapse
|
45
|
Cook H, Simard M, Niemann N, Gillies C, Palmans H, Hussein M, Bouchard H, Royle G, Lourenço A. OC-0937 Optimising tissue-equivalent materials for proton therapy. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02717-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
46
|
Saez J, Bar-Deroma R, Bogaert E, Cayez R, Chow T, Esposito M, Feygelman V, Monti A, Garcia-Miguel J, Gershkevitsh E, Goossens J, Herrero C, Hussein M, Khamphan C, Lechner W, Lemire M, Nevelsky A, Nguyen D, Paganini L, Passler M, Ramos Garcia L, Russo S, Shakeshaft J, Vieillevigne L, Hernandez V. OC-0120 MLC modelling assessment with a set of standardized tests: Results from a multicentric study. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02496-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
47
|
Hussein M, Lehmann J, Clark C. OC-0753 Robustness of spine SABR plans to delivery errors within machine tolerance: multicentre analysis. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02659-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
48
|
Aaltonen T, Amerio S, Amidei D, Anastassov A, Annovi A, Antos J, Apollinari G, Appel JA, Arisawa T, Artikov A, Asaadi J, Ashmanskas W, Auerbach B, Aurisano A, Azfar F, Badgett W, Bae T, Barbaro-Galtieri A, Barnes VE, Barnett BA, Barria P, Bartos P, Bauce M, Bedeschi F, Behari S, Bellettini G, Bellinger J, Benjamin D, Beretvas A, Bhatti A, Bland KR, Blumenfeld B, Bocci A, Bodek A, Bortoletto D, Boudreau J, Boveia A, Brigliadori L, Bromberg C, Brucken E, Budagov J, Budd HS, Burkett K, Busetto G, Bussey P, Butti P, Buzatu A, Calamba A, Camarda S, Campanelli M, Carls B, Carlsmith D, Carosi R, Carrillo S, Casal B, Casarsa M, Castro A, Catastini P, Cauz D, Cavaliere V, Cerri A, Cerrito L, Chen YC, Chertok M, Chiarelli G, Chlachidze G, Cho K, Chokheli D, Clark A, Clarke C, Convery ME, Conway J, Corbo M, Cordelli M, Cox CA, Cox DJ, Cremonesi M, Cruz D, Cuevas J, Culbertson R, d'Ascenzo N, Datta M, de Barbaro P, Demortier L, Deninno M, D'Errico M, Devoto F, Di Canto A, Di Ruzza B, Dittmann JR, Donati S, D'Onofrio M, Dorigo M, Driutti A, Ebina K, Edgar R, Elagin A, Erbacher R, Errede S, Esham B, Farrington S, Fernández Ramos JP, Field R, Flanagan G, Forrest R, Franklin M, Freeman JC, Frisch H, Funakoshi Y, Galloni C, Garfinkel AF, Garosi P, Gerberich H, Gerchtein E, Giagu S, Giakoumopoulou V, Gibson K, Ginsburg CM, Giokaris N, Giromini P, Glagolev V, Glenzinski D, Gold M, Goldin D, Golossanov A, Gomez G, Gomez-Ceballos G, Goncharov M, González López O, Gorelov I, Goshaw AT, Goulianos K, Gramellini E, Grosso-Pilcher C, Guimaraes da Costa J, Hahn SR, Han JY, Happacher F, Hara K, Hare M, Harr RF, Harrington-Taber T, Hatakeyama K, Hays C, Heinrich J, Herndon M, Hocker A, Hong Z, Hopkins W, Hou S, Hughes RE, Husemann U, Hussein M, Huston J, Introzzi G, Iori M, Ivanov A, James E, Jang D, Jayatilaka B, Jeon EJ, Jindariani S, Jones M, Joo KK, Jun SY, Junk TR, Kambeitz M, Kamon T, Karchin PE, Kasmi A, Kato Y, Ketchum W, Keung J, Kilminster B, Kim DH, Kim HS, Kim JE, Kim MJ, Kim SH, Kim SB, Kim YJ, Kim YK, Kimura N, Kirby M, Kondo K, Kong DJ, Konigsberg J, Kotwal AV, Kreps M, Kroll J, Kruse M, Kuhr T, Kurata M, Laasanen AT, Lammel S, Lancaster M, Lannon K, Latino G, Lee HS, Lee JS, Leo S, Leone S, Lewis JD, Limosani A, Lipeles E, Lister A, Liu Q, Liu T, Lockwitz S, Loginov A, Lucchesi D, Lucà A, Lueck J, Lujan P, Lukens P, Lungu G, Lys J, Lysak R, Madrak R, Maestro P, Malik S, Manca G, Manousakis-Katsikakis A, Marchese L, Margaroli F, Marino P, Matera K, Mattson ME, Mazzacane A, Mazzanti P, McNulty R, Mehta A, Mehtala P, Menzione A, Mesropian C, Miao T, Michielin E, Mietlicki D, Mitra A, Miyake H, Moed S, Moggi N, Moon CS, Moore R, Morello MJ, Mukherjee A, Muller T, Murat P, Mussini M, Nachtman J, Nagai Y, Naganoma J, Nakano I, Napier A, Nett J, Nigmanov T, Nodulman L, Noh SY, Norniella O, Oakes L, Oh SH, Oh YD, Okusawa T, Orava R, Ortolan L, Pagliarone C, Palencia E, Palni P, Papadimitriou V, Parker W, Pauletta G, Paulini M, Paus C, Phillips TJ, Piacentino G, Pianori E, Pilot J, Pitts K, Plager C, Pondrom L, Poprocki S, Potamianos K, Pranko A, Prokoshin F, Ptohos F, Punzi G, Redondo Fernández I, Renton P, Rescigno M, Rimondi F, Ristori L, Robson A, Rodriguez T, Rolli S, Ronzani M, Roser R, Rosner JL, Ruffini F, Ruiz A, Russ J, Rusu V, Sakumoto WK, Sakurai Y, Santi L, Sato K, Saveliev V, Savoy-Navarro A, Schlabach P, Schmidt EE, Schwarz T, Scodellaro L, Scuri F, Seidel S, Seiya Y, Semenov A, Sforza F, Shalhout SZ, Shears T, Shepard PF, Shimojima M, Shochet M, Shreyber-Tecker I, Simonenko A, Sliwa K, Smith JR, Snider FD, Song H, Sorin V, St Denis R, Stancari M, Stentz D, Strologas J, Sudo Y, Sukhanov A, Suslov I, Takemasa K, Takeuchi Y, Tang J, Tecchio M, Teng PK, Thom J, Thomson E, Thukral V, Toback D, Tokar S, Tollefson K, Tomura T, Torre S, Torretta D, Totaro P, Trovato M, Ukegawa F, Uozumi S, Vázquez F, Velev G, Vellidis K, Vernieri C, Vidal M, Vilar R, Vizán J, Vogel M, Volpi G, Wagner P, Wallny R, Wang SM, Waters D, Wester WC, Whiteson D, Wicklund AB, Wilbur S, Williams HH, Wilson JS, Wilson P, Winer BL, Wittich P, Wolbers S, Wolfmeister H, Wright T, Wu X, Wu Z, Yamamoto K, Yamato D, Yang T, Yang UK, Yang YC, Yao WM, Yeh GP, Yi K, Yoh J, Yorita K, Yoshida T, Yu GB, Yu I, Zanetti AM, Zeng Y, Zhou C, Zucchelli S. High-precision measurement of the W boson mass with the CDF II detector. Science 2022; 376:170-176. [PMID: 35389814 DOI: 10.1126/science.abk1781] [Citation(s) in RCA: 77] [Impact Index Per Article: 38.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
The mass of the W boson, a mediator of the weak force between elementary particles, is tightly constrained by the symmetries of the standard model of particle physics. The Higgs boson was the last missing component of the model. After observation of the Higgs boson, a measurement of the W boson mass provides a stringent test of the model. We measure the W boson mass, MW, using data corresponding to 8.8 inverse femtobarns of integrated luminosity collected in proton-antiproton collisions at a 1.96 tera-electron volt center-of-mass energy with the CDF II detector at the Fermilab Tevatron collider. A sample of approximately 4 million W boson candidates is used to obtain [Formula: see text], the precision of which exceeds that of all previous measurements combined (stat, statistical uncertainty; syst, systematic uncertainty; MeV, mega-electron volts; c, speed of light in a vacuum). This measurement is in significant tension with the standard model expectation.
Collapse
Affiliation(s)
| | - T Aaltonen
- Division of High Energy Physics, Department of Physics, University of Helsinki, FIN-00014, Helsinki, Finland.,Helsinki Institute of Physics, FIN-00014, Helsinki, Finland
| | - S Amerio
- Istituto Nazionale di Fisica Nucleare, Sezione di Padova, I-35131 Padova, Italy.,University of Padova, I-35131 Padova, Italy
| | - D Amidei
- University of Michigan, Ann Arbor, MI 48109, USA
| | - A Anastassov
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - A Annovi
- Laboratori Nazionali di Frascati, Istituto Nazionale di Fisica Nucleare, I-00044 Frascati, Italy
| | - J Antos
- Comenius University, 842 48 Bratislava, Slovakia.,Institute of Experimental Physics, 040 01 Kosice, Slovakia
| | - G Apollinari
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - J A Appel
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | | | - A Artikov
- Joint Institute for Nuclear Research, Dubna RU-141980, Russia
| | - J Asaadi
- Mitchell Institute for Fundamental Physics and Astronomy, Texas A&M University, College Station, TX 77843, USA
| | - W Ashmanskas
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - B Auerbach
- Argonne National Laboratory, Argonne, IL 60439, USA
| | - A Aurisano
- Mitchell Institute for Fundamental Physics and Astronomy, Texas A&M University, College Station, TX 77843, USA
| | - F Azfar
- University of Oxford, Oxford OX1 3RH, UK
| | - W Badgett
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - T Bae
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - A Barbaro-Galtieri
- Ernest Orlando Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA
| | - V E Barnes
- Purdue University, West Lafayette, IN 47907, USA
| | - B A Barnett
- The Johns Hopkins University, Baltimore, MD 21218, USA
| | - P Barria
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,University of Siena, I-53100 Siena, Italy
| | - P Bartos
- Comenius University, 842 48 Bratislava, Slovakia.,Institute of Experimental Physics, 040 01 Kosice, Slovakia
| | - M Bauce
- Istituto Nazionale di Fisica Nucleare, Sezione di Padova, I-35131 Padova, Italy.,University of Padova, I-35131 Padova, Italy
| | - F Bedeschi
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy
| | - S Behari
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - G Bellettini
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,University of Pisa, I-56126 Pisa, Italy
| | - J Bellinger
- University of Wisconsin-Madison, Madison, WI 53706, USA
| | | | - A Beretvas
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - A Bhatti
- The Rockefeller University, New York, NY 10065, USA
| | - K R Bland
- Baylor University, Waco, TX 76798, USA
| | - B Blumenfeld
- The Johns Hopkins University, Baltimore, MD 21218, USA
| | - A Bocci
- Duke University, Durham, NC 27708, USA
| | - A Bodek
- University of Rochester, Rochester, NY 14627, USA
| | - D Bortoletto
- Purdue University, West Lafayette, IN 47907, USA
| | - J Boudreau
- University of Pittsburgh, Pittsburgh, PA 15260, USA
| | - A Boveia
- Enrico Fermi Institute, University of Chicago, Chicago, IL 60637, USA
| | - L Brigliadori
- Istituto Nazionale di Fisica Nucleare Bologna, I-40127 Bologna, Italy.,University of Bologna, I-40127 Bologna, Italy
| | - C Bromberg
- Michigan State University, East Lansing, MI 48824, USA
| | - E Brucken
- Division of High Energy Physics, Department of Physics, University of Helsinki, FIN-00014, Helsinki, Finland.,Helsinki Institute of Physics, FIN-00014, Helsinki, Finland
| | - J Budagov
- Joint Institute for Nuclear Research, Dubna RU-141980, Russia
| | - H S Budd
- University of Rochester, Rochester, NY 14627, USA
| | - K Burkett
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - G Busetto
- Istituto Nazionale di Fisica Nucleare, Sezione di Padova, I-35131 Padova, Italy.,University of Padova, I-35131 Padova, Italy
| | - P Bussey
- Glasgow University, Glasgow G12 8QQ, UK
| | - P Butti
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,University of Pisa, I-56126 Pisa, Italy
| | - A Buzatu
- Glasgow University, Glasgow G12 8QQ, UK
| | - A Calamba
- Carnegie Mellon University, Pittsburgh, PA 15213, USA
| | - S Camarda
- Institut de Fisica d'Altes Energies, ICREA, Universitat Autonoma de Barcelona, E-08193 Bellaterra (Barcelona), Spain
| | | | - B Carls
- University of Illinois, Urbana, IL 61801, USA
| | - D Carlsmith
- University of Wisconsin-Madison, Madison, WI 53706, USA
| | - R Carosi
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy
| | - S Carrillo
- University of Florida, Gainesville, FL 32611, USA
| | - B Casal
- Instituto de Fisica de Cantabria, CSIC-University of Cantabria, 39005 Santander, Spain
| | - M Casarsa
- Istituto Nazionale di Fisica Nucleare Trieste, I-34127 Trieste, Italy
| | - A Castro
- Istituto Nazionale di Fisica Nucleare Bologna, I-40127 Bologna, Italy.,University of Bologna, I-40127 Bologna, Italy
| | - P Catastini
- Harvard University, Cambridge, MA 02138, USA
| | - D Cauz
- Istituto Nazionale di Fisica Nucleare Trieste, I-34127 Trieste, Italy.,Gruppo Collegato di Udine, I-33100 Udine, Italy.,University of Udine, I-33100 Udine, Italy
| | - V Cavaliere
- University of Illinois, Urbana, IL 61801, USA
| | - A Cerri
- Ernest Orlando Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA
| | - L Cerrito
- University College London, London WC1E 6BT, UK
| | - Y C Chen
- Institute of Physics, Academia Sinica, Taipei, Taiwan 11529, Republic of China
| | - M Chertok
- University of California, Davis, Davis, CA 95616, USA
| | - G Chiarelli
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy
| | - G Chlachidze
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - K Cho
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - D Chokheli
- Joint Institute for Nuclear Research, Dubna RU-141980, Russia
| | - A Clark
- University of Geneva, CH-1211 Geneva 4, Switzerland
| | - C Clarke
- Wayne State University, Detroit, MI 48201, USA
| | - M E Convery
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - J Conway
- University of California, Davis, Davis, CA 95616, USA
| | - M Corbo
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - M Cordelli
- Laboratori Nazionali di Frascati, Istituto Nazionale di Fisica Nucleare, I-00044 Frascati, Italy
| | - C A Cox
- University of California, Davis, Davis, CA 95616, USA
| | - D J Cox
- University of California, Davis, Davis, CA 95616, USA
| | - M Cremonesi
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy
| | - D Cruz
- Mitchell Institute for Fundamental Physics and Astronomy, Texas A&M University, College Station, TX 77843, USA
| | - J Cuevas
- Instituto de Fisica de Cantabria, CSIC-University of Cantabria, 39005 Santander, Spain
| | - R Culbertson
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - N d'Ascenzo
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - M Datta
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - P de Barbaro
- University of Rochester, Rochester, NY 14627, USA
| | - L Demortier
- The Rockefeller University, New York, NY 10065, USA
| | - M Deninno
- Istituto Nazionale di Fisica Nucleare Bologna, I-40127 Bologna, Italy
| | - M D'Errico
- Istituto Nazionale di Fisica Nucleare, Sezione di Padova, I-35131 Padova, Italy.,University of Padova, I-35131 Padova, Italy
| | - F Devoto
- Division of High Energy Physics, Department of Physics, University of Helsinki, FIN-00014, Helsinki, Finland.,Helsinki Institute of Physics, FIN-00014, Helsinki, Finland
| | - A Di Canto
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,University of Pisa, I-56126 Pisa, Italy
| | - B Di Ruzza
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | | | - S Donati
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,University of Pisa, I-56126 Pisa, Italy
| | - M D'Onofrio
- University of Liverpool, Liverpool L69 7ZE, UK
| | - M Dorigo
- Istituto Nazionale di Fisica Nucleare Trieste, I-34127 Trieste, Italy.,University of Trieste, I-34127 Trieste, Italy
| | - A Driutti
- Istituto Nazionale di Fisica Nucleare Trieste, I-34127 Trieste, Italy.,Gruppo Collegato di Udine, I-33100 Udine, Italy.,University of Udine, I-33100 Udine, Italy
| | - K Ebina
- Waseda University, Tokyo 169, Japan
| | - R Edgar
- University of Michigan, Ann Arbor, MI 48109, USA
| | - A Elagin
- Enrico Fermi Institute, University of Chicago, Chicago, IL 60637, USA
| | - R Erbacher
- University of California, Davis, Davis, CA 95616, USA
| | - S Errede
- University of Illinois, Urbana, IL 61801, USA
| | - B Esham
- University of Illinois, Urbana, IL 61801, USA
| | | | - J P Fernández Ramos
- Centro de Investigaciones Energeticas Medioambientales y Tecnologicas, E-28040 Madrid, Spain
| | - R Field
- University of Florida, Gainesville, FL 32611, USA
| | - G Flanagan
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - R Forrest
- University of California, Davis, Davis, CA 95616, USA
| | - M Franklin
- Harvard University, Cambridge, MA 02138, USA
| | - J C Freeman
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - H Frisch
- Enrico Fermi Institute, University of Chicago, Chicago, IL 60637, USA
| | | | - C Galloni
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,University of Pisa, I-56126 Pisa, Italy
| | | | - P Garosi
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,University of Siena, I-53100 Siena, Italy
| | - H Gerberich
- University of Illinois, Urbana, IL 61801, USA
| | - E Gerchtein
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - S Giagu
- Istituto Nazionale di Fisica Nucleare, Sezione di Roma 1, I-00185 Roma, Italy
| | - V Giakoumopoulou
- National and Kapodistrian University of Athens, 157 71 Athens, Greece
| | - K Gibson
- University of Pittsburgh, Pittsburgh, PA 15260, USA
| | - C M Ginsburg
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - N Giokaris
- National and Kapodistrian University of Athens, 157 71 Athens, Greece
| | - P Giromini
- Laboratori Nazionali di Frascati, Istituto Nazionale di Fisica Nucleare, I-00044 Frascati, Italy
| | - V Glagolev
- Joint Institute for Nuclear Research, Dubna RU-141980, Russia
| | - D Glenzinski
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - M Gold
- University of New Mexico, Albuquerque, NM 87131, USA
| | - D Goldin
- Mitchell Institute for Fundamental Physics and Astronomy, Texas A&M University, College Station, TX 77843, USA
| | - A Golossanov
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - G Gomez
- Instituto de Fisica de Cantabria, CSIC-University of Cantabria, 39005 Santander, Spain
| | | | - M Goncharov
- Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - O González López
- Centro de Investigaciones Energeticas Medioambientales y Tecnologicas, E-28040 Madrid, Spain
| | - I Gorelov
- University of New Mexico, Albuquerque, NM 87131, USA
| | | | - K Goulianos
- The Rockefeller University, New York, NY 10065, USA
| | - E Gramellini
- Istituto Nazionale di Fisica Nucleare Bologna, I-40127 Bologna, Italy
| | - C Grosso-Pilcher
- Enrico Fermi Institute, University of Chicago, Chicago, IL 60637, USA
| | | | - S R Hahn
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - J Y Han
- University of Rochester, Rochester, NY 14627, USA
| | - F Happacher
- Laboratori Nazionali di Frascati, Istituto Nazionale di Fisica Nucleare, I-00044 Frascati, Italy
| | - K Hara
- University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - M Hare
- Tufts University, Medford, MA 02155, USA
| | - R F Harr
- Wayne State University, Detroit, MI 48201, USA
| | | | | | - C Hays
- University of Oxford, Oxford OX1 3RH, UK
| | - J Heinrich
- University of Pennsylvania, Philadelphia, PA 19104, USA
| | - M Herndon
- University of Wisconsin-Madison, Madison, WI 53706, USA
| | - A Hocker
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - Z Hong
- Mitchell Institute for Fundamental Physics and Astronomy, Texas A&M University, College Station, TX 77843, USA
| | - W Hopkins
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - S Hou
- Institute of Physics, Academia Sinica, Taipei, Taiwan 11529, Republic of China
| | - R E Hughes
- The Ohio State University, Columbus, OH 43210, USA
| | - U Husemann
- Yale University, New Haven, CT 06520, USA
| | - M Hussein
- Michigan State University, East Lansing, MI 48824, USA
| | - J Huston
- Michigan State University, East Lansing, MI 48824, USA
| | - G Introzzi
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,Istituto Nazionale di Fisica Nucleare Pavia, I-27100 Pavia, Italy.,University of Pavia, I-27100 Pavia, Italy
| | - M Iori
- Istituto Nazionale di Fisica Nucleare, Sezione di Roma 1, I-00185 Roma, Italy.,Sapienza Università di Roma, I-00185 Roma, Italy
| | - A Ivanov
- University of California, Davis, Davis, CA 95616, USA
| | - E James
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - D Jang
- Carnegie Mellon University, Pittsburgh, PA 15213, USA
| | - B Jayatilaka
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - E J Jeon
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - S Jindariani
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - M Jones
- Purdue University, West Lafayette, IN 47907, USA
| | - K K Joo
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - S Y Jun
- Carnegie Mellon University, Pittsburgh, PA 15213, USA
| | - T R Junk
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - M Kambeitz
- Institut für Experimentelle Kernphysik, Karlsruhe Institute of Technology, D-76131 Karlsruhe, Germany
| | - T Kamon
- Mitchell Institute for Fundamental Physics and Astronomy, Texas A&M University, College Station, TX 77843, USA.,Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - P E Karchin
- Wayne State University, Detroit, MI 48201, USA
| | - A Kasmi
- Baylor University, Waco, TX 76798, USA
| | - Y Kato
- Osaka City University, Osaka 558-8585, Japan
| | - W Ketchum
- Enrico Fermi Institute, University of Chicago, Chicago, IL 60637, USA
| | - J Keung
- University of Pennsylvania, Philadelphia, PA 19104, USA
| | - B Kilminster
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - D H Kim
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - H S Kim
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - J E Kim
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - M J Kim
- Laboratori Nazionali di Frascati, Istituto Nazionale di Fisica Nucleare, I-00044 Frascati, Italy
| | - S H Kim
- University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - S B Kim
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - Y J Kim
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - Y K Kim
- Enrico Fermi Institute, University of Chicago, Chicago, IL 60637, USA
| | - N Kimura
- Waseda University, Tokyo 169, Japan
| | - M Kirby
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - K Kondo
- Waseda University, Tokyo 169, Japan
| | - D J Kong
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - J Konigsberg
- University of Florida, Gainesville, FL 32611, USA
| | | | - M Kreps
- Institut für Experimentelle Kernphysik, Karlsruhe Institute of Technology, D-76131 Karlsruhe, Germany
| | - J Kroll
- University of Pennsylvania, Philadelphia, PA 19104, USA
| | - M Kruse
- Duke University, Durham, NC 27708, USA
| | - T Kuhr
- Institut für Experimentelle Kernphysik, Karlsruhe Institute of Technology, D-76131 Karlsruhe, Germany
| | - M Kurata
- University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - A T Laasanen
- Purdue University, West Lafayette, IN 47907, USA
| | - S Lammel
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - M Lancaster
- University College London, London WC1E 6BT, UK
| | - K Lannon
- The Ohio State University, Columbus, OH 43210, USA
| | - G Latino
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,University of Siena, I-53100 Siena, Italy
| | - H S Lee
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - J S Lee
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - S Leo
- University of Illinois, Urbana, IL 61801, USA
| | - S Leone
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy
| | - J D Lewis
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | | | - E Lipeles
- University of Pennsylvania, Philadelphia, PA 19104, USA
| | - A Lister
- University of Geneva, CH-1211 Geneva 4, Switzerland
| | - Q Liu
- Purdue University, West Lafayette, IN 47907, USA
| | - T Liu
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - S Lockwitz
- Yale University, New Haven, CT 06520, USA
| | - A Loginov
- Yale University, New Haven, CT 06520, USA
| | - D Lucchesi
- Istituto Nazionale di Fisica Nucleare, Sezione di Padova, I-35131 Padova, Italy.,University of Padova, I-35131 Padova, Italy
| | - A Lucà
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA.,Laboratori Nazionali di Frascati, Istituto Nazionale di Fisica Nucleare, I-00044 Frascati, Italy
| | - J Lueck
- Institut für Experimentelle Kernphysik, Karlsruhe Institute of Technology, D-76131 Karlsruhe, Germany
| | - P Lujan
- Ernest Orlando Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA
| | - P Lukens
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - G Lungu
- The Rockefeller University, New York, NY 10065, USA
| | - J Lys
- Ernest Orlando Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA
| | - R Lysak
- Comenius University, 842 48 Bratislava, Slovakia.,Institute of Experimental Physics, 040 01 Kosice, Slovakia
| | - R Madrak
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - P Maestro
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,University of Siena, I-53100 Siena, Italy
| | - S Malik
- The Rockefeller University, New York, NY 10065, USA
| | - G Manca
- University of Liverpool, Liverpool L69 7ZE, UK
| | | | - L Marchese
- Istituto Nazionale di Fisica Nucleare Bologna, I-40127 Bologna, Italy
| | - F Margaroli
- Istituto Nazionale di Fisica Nucleare, Sezione di Roma 1, I-00185 Roma, Italy
| | - P Marino
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,Scuola Normale Superiore, I-56126 Pisa, Italy
| | - K Matera
- University of Illinois, Urbana, IL 61801, USA
| | - M E Mattson
- Wayne State University, Detroit, MI 48201, USA
| | - A Mazzacane
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - P Mazzanti
- Istituto Nazionale di Fisica Nucleare Bologna, I-40127 Bologna, Italy
| | - R McNulty
- University of Liverpool, Liverpool L69 7ZE, UK
| | - A Mehta
- University of Liverpool, Liverpool L69 7ZE, UK
| | - P Mehtala
- Division of High Energy Physics, Department of Physics, University of Helsinki, FIN-00014, Helsinki, Finland.,Helsinki Institute of Physics, FIN-00014, Helsinki, Finland
| | - A Menzione
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy
| | - C Mesropian
- The Rockefeller University, New York, NY 10065, USA
| | - T Miao
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - E Michielin
- Istituto Nazionale di Fisica Nucleare, Sezione di Padova, I-35131 Padova, Italy.,University of Padova, I-35131 Padova, Italy
| | - D Mietlicki
- University of Michigan, Ann Arbor, MI 48109, USA
| | - A Mitra
- Institute of Physics, Academia Sinica, Taipei, Taiwan 11529, Republic of China
| | - H Miyake
- University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - S Moed
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - N Moggi
- Istituto Nazionale di Fisica Nucleare Bologna, I-40127 Bologna, Italy
| | - C S Moon
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - R Moore
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - M J Morello
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,Scuola Normale Superiore, I-56126 Pisa, Italy
| | - A Mukherjee
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - Th Muller
- Institut für Experimentelle Kernphysik, Karlsruhe Institute of Technology, D-76131 Karlsruhe, Germany
| | - P Murat
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - M Mussini
- Istituto Nazionale di Fisica Nucleare Bologna, I-40127 Bologna, Italy.,University of Bologna, I-40127 Bologna, Italy
| | - J Nachtman
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - Y Nagai
- University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | | | - I Nakano
- Okayama University, Okayama 700-8530, Japan
| | - A Napier
- Tufts University, Medford, MA 02155, USA
| | - J Nett
- Mitchell Institute for Fundamental Physics and Astronomy, Texas A&M University, College Station, TX 77843, USA
| | - T Nigmanov
- University of Pittsburgh, Pittsburgh, PA 15260, USA
| | - L Nodulman
- Argonne National Laboratory, Argonne, IL 60439, USA
| | - S Y Noh
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - O Norniella
- University of Illinois, Urbana, IL 61801, USA
| | - L Oakes
- University of Oxford, Oxford OX1 3RH, UK
| | - S H Oh
- Duke University, Durham, NC 27708, USA
| | - Y D Oh
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - T Okusawa
- Osaka City University, Osaka 558-8585, Japan
| | - R Orava
- Division of High Energy Physics, Department of Physics, University of Helsinki, FIN-00014, Helsinki, Finland.,Helsinki Institute of Physics, FIN-00014, Helsinki, Finland
| | - L Ortolan
- Institut de Fisica d'Altes Energies, ICREA, Universitat Autonoma de Barcelona, E-08193 Bellaterra (Barcelona), Spain
| | - C Pagliarone
- Istituto Nazionale di Fisica Nucleare Trieste, I-34127 Trieste, Italy
| | - E Palencia
- Instituto de Fisica de Cantabria, CSIC-University of Cantabria, 39005 Santander, Spain
| | - P Palni
- University of New Mexico, Albuquerque, NM 87131, USA
| | - V Papadimitriou
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - W Parker
- University of Wisconsin-Madison, Madison, WI 53706, USA
| | - G Pauletta
- Istituto Nazionale di Fisica Nucleare Trieste, I-34127 Trieste, Italy.,Gruppo Collegato di Udine, I-33100 Udine, Italy.,University of Udine, I-33100 Udine, Italy
| | - M Paulini
- Carnegie Mellon University, Pittsburgh, PA 15213, USA
| | - C Paus
- Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | | | - G Piacentino
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - E Pianori
- University of Pennsylvania, Philadelphia, PA 19104, USA
| | - J Pilot
- University of California, Davis, Davis, CA 95616, USA
| | - K Pitts
- University of Illinois, Urbana, IL 61801, USA
| | - C Plager
- University of California, Los Angeles, Los Angeles, CA 90024, USA
| | - L Pondrom
- University of Wisconsin-Madison, Madison, WI 53706, USA
| | - S Poprocki
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - K Potamianos
- Ernest Orlando Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA
| | - A Pranko
- Ernest Orlando Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA
| | - F Prokoshin
- Joint Institute for Nuclear Research, Dubna RU-141980, Russia
| | - F Ptohos
- Laboratori Nazionali di Frascati, Istituto Nazionale di Fisica Nucleare, I-00044 Frascati, Italy
| | - G Punzi
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,University of Pisa, I-56126 Pisa, Italy
| | - I Redondo Fernández
- Centro de Investigaciones Energeticas Medioambientales y Tecnologicas, E-28040 Madrid, Spain
| | - P Renton
- University of Oxford, Oxford OX1 3RH, UK
| | - M Rescigno
- Istituto Nazionale di Fisica Nucleare, Sezione di Roma 1, I-00185 Roma, Italy
| | - F Rimondi
- Istituto Nazionale di Fisica Nucleare Bologna, I-40127 Bologna, Italy
| | - L Ristori
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA.,Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy
| | - A Robson
- Glasgow University, Glasgow G12 8QQ, UK
| | - T Rodriguez
- University of Pennsylvania, Philadelphia, PA 19104, USA
| | - S Rolli
- Tufts University, Medford, MA 02155, USA
| | - M Ronzani
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,University of Pisa, I-56126 Pisa, Italy
| | - R Roser
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - J L Rosner
- Enrico Fermi Institute, University of Chicago, Chicago, IL 60637, USA
| | - F Ruffini
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,University of Siena, I-53100 Siena, Italy
| | - A Ruiz
- Instituto de Fisica de Cantabria, CSIC-University of Cantabria, 39005 Santander, Spain
| | - J Russ
- Carnegie Mellon University, Pittsburgh, PA 15213, USA
| | - V Rusu
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - W K Sakumoto
- University of Rochester, Rochester, NY 14627, USA
| | | | - L Santi
- Istituto Nazionale di Fisica Nucleare Trieste, I-34127 Trieste, Italy.,Gruppo Collegato di Udine, I-33100 Udine, Italy.,University of Udine, I-33100 Udine, Italy
| | - K Sato
- University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - V Saveliev
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - A Savoy-Navarro
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - P Schlabach
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - E E Schmidt
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - T Schwarz
- University of Michigan, Ann Arbor, MI 48109, USA
| | - L Scodellaro
- Instituto de Fisica de Cantabria, CSIC-University of Cantabria, 39005 Santander, Spain
| | - F Scuri
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy
| | - S Seidel
- University of New Mexico, Albuquerque, NM 87131, USA
| | - Y Seiya
- Osaka City University, Osaka 558-8585, Japan
| | - A Semenov
- Joint Institute for Nuclear Research, Dubna RU-141980, Russia
| | - F Sforza
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,University of Pisa, I-56126 Pisa, Italy
| | - S Z Shalhout
- University of California, Davis, Davis, CA 95616, USA
| | - T Shears
- University of Liverpool, Liverpool L69 7ZE, UK
| | - P F Shepard
- University of Pittsburgh, Pittsburgh, PA 15260, USA
| | - M Shimojima
- University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - M Shochet
- Enrico Fermi Institute, University of Chicago, Chicago, IL 60637, USA
| | - I Shreyber-Tecker
- Institution for Theoretical and Experimental Physics, ITEP, Moscow 117259, Russia
| | - A Simonenko
- Joint Institute for Nuclear Research, Dubna RU-141980, Russia
| | - K Sliwa
- Tufts University, Medford, MA 02155, USA
| | - J R Smith
- University of California, Davis, Davis, CA 95616, USA
| | - F D Snider
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - H Song
- University of Pittsburgh, Pittsburgh, PA 15260, USA
| | - V Sorin
- Institut de Fisica d'Altes Energies, ICREA, Universitat Autonoma de Barcelona, E-08193 Bellaterra (Barcelona), Spain
| | | | - M Stancari
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - D Stentz
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - J Strologas
- University of New Mexico, Albuquerque, NM 87131, USA
| | - Y Sudo
- University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - A Sukhanov
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - I Suslov
- Joint Institute for Nuclear Research, Dubna RU-141980, Russia
| | - K Takemasa
- University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - Y Takeuchi
- University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - J Tang
- Enrico Fermi Institute, University of Chicago, Chicago, IL 60637, USA
| | - M Tecchio
- University of Michigan, Ann Arbor, MI 48109, USA
| | - P K Teng
- Institute of Physics, Academia Sinica, Taipei, Taiwan 11529, Republic of China
| | - J Thom
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - E Thomson
- University of Pennsylvania, Philadelphia, PA 19104, USA
| | - V Thukral
- Mitchell Institute for Fundamental Physics and Astronomy, Texas A&M University, College Station, TX 77843, USA
| | - D Toback
- Mitchell Institute for Fundamental Physics and Astronomy, Texas A&M University, College Station, TX 77843, USA
| | - S Tokar
- Comenius University, 842 48 Bratislava, Slovakia.,Institute of Experimental Physics, 040 01 Kosice, Slovakia
| | - K Tollefson
- Michigan State University, East Lansing, MI 48824, USA
| | - T Tomura
- University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - S Torre
- Laboratori Nazionali di Frascati, Istituto Nazionale di Fisica Nucleare, I-00044 Frascati, Italy
| | - D Torretta
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - P Totaro
- Istituto Nazionale di Fisica Nucleare, Sezione di Padova, I-35131 Padova, Italy
| | - M Trovato
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,Scuola Normale Superiore, I-56126 Pisa, Italy
| | - F Ukegawa
- University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - S Uozumi
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - F Vázquez
- University of Florida, Gainesville, FL 32611, USA
| | - G Velev
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - K Vellidis
- National and Kapodistrian University of Athens, 157 71 Athens, Greece
| | - C Vernieri
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,Scuola Normale Superiore, I-56126 Pisa, Italy
| | - M Vidal
- Purdue University, West Lafayette, IN 47907, USA
| | - R Vilar
- Instituto de Fisica de Cantabria, CSIC-University of Cantabria, 39005 Santander, Spain
| | - J Vizán
- Instituto de Fisica de Cantabria, CSIC-University of Cantabria, 39005 Santander, Spain
| | - M Vogel
- University of New Mexico, Albuquerque, NM 87131, USA
| | - G Volpi
- Laboratori Nazionali di Frascati, Istituto Nazionale di Fisica Nucleare, I-00044 Frascati, Italy
| | - P Wagner
- University of Pennsylvania, Philadelphia, PA 19104, USA
| | - R Wallny
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - S M Wang
- Institute of Physics, Academia Sinica, Taipei, Taiwan 11529, Republic of China
| | - D Waters
- University College London, London WC1E 6BT, UK
| | - W C Wester
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - D Whiteson
- University of Pennsylvania, Philadelphia, PA 19104, USA
| | - A B Wicklund
- Argonne National Laboratory, Argonne, IL 60439, USA
| | - S Wilbur
- University of California, Davis, Davis, CA 95616, USA
| | - H H Williams
- University of Pennsylvania, Philadelphia, PA 19104, USA
| | - J S Wilson
- University of Michigan, Ann Arbor, MI 48109, USA
| | - P Wilson
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - B L Winer
- The Ohio State University, Columbus, OH 43210, USA
| | - P Wittich
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - S Wolbers
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | | | - T Wright
- University of Michigan, Ann Arbor, MI 48109, USA
| | - X Wu
- University of Geneva, CH-1211 Geneva 4, Switzerland
| | - Z Wu
- Baylor University, Waco, TX 76798, USA
| | - K Yamamoto
- Osaka City University, Osaka 558-8585, Japan
| | - D Yamato
- Osaka City University, Osaka 558-8585, Japan
| | - T Yang
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - U K Yang
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - Y C Yang
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - W-M Yao
- Ernest Orlando Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA
| | - G P Yeh
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - K Yi
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - J Yoh
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - K Yorita
- Waseda University, Tokyo 169, Japan
| | - T Yoshida
- Osaka City University, Osaka 558-8585, Japan
| | - G B Yu
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - I Yu
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - A M Zanetti
- Istituto Nazionale di Fisica Nucleare Trieste, I-34127 Trieste, Italy
| | - Y Zeng
- Duke University, Durham, NC 27708, USA
| | - C Zhou
- Duke University, Durham, NC 27708, USA
| | - S Zucchelli
- Istituto Nazionale di Fisica Nucleare Bologna, I-40127 Bologna, Italy.,University of Bologna, I-40127 Bologna, Italy
| |
Collapse
|
49
|
Lehmann J, Hussein M, Barry M, Siva S, Moore A, Chu M, Díez P, Eaton DJ, Harwood J, Lonski P, Claridge Mackonis E, Meehan C, Patel R, Ray X, Shaw M, Shepherd J, Smyth G, Standen TS, Subramanian B, Greer P, Clark CH. SEAFARER – A new concept for validating radiotherapy patient specific QA for clinical trials and clinical practice. Radiother Oncol 2022; 171:121-128. [DOI: 10.1016/j.radonc.2022.04.019] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2021] [Revised: 03/22/2022] [Accepted: 04/14/2022] [Indexed: 01/12/2023]
|
50
|
Garon E, Cho B, Luft A, Alatorre-Alexander J, Geater S, Trukhin D, Kim SW, Ursol G, Hussein M, Lim F, Yang CT, Araujo L, Saito H, Reinmuth N, Medic N, Mann H, Shi X, Peters S, Mok T, Johnson M. 5MO Patient reported outcomes (PROs) with 1L durvalumab (D), with or without tremelimumab (T), plus chemotherapy (CT) in metastatic (m) NSCLC: Results from POSEIDON. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.02.014] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|